Document:

EX-10.36

 Exhibit 10.36 
 EXCLUSIVE DISTRIBUTION AGREEMENT 
 This Exclusive Distribution
Agreement (this “Agreement”) is entered into as of 29th June 2011 (the “Effective Date”), between Oncogenerix, Inc., a Nevada corporation having offices at 3069 Pignatelli Crescent, Mt. Pleasant, SC
29466 (“Oncogenerix”) and Rosemont Pharmaceuticals Limited (company number: 00924648), a company incorporated in England and Wales and having offices at Rosemont House, Yorkdale Industrial Park, Braithwaite Street, Leeds LS II 9XE,
United Kingdom (“Rosemont”). 
 RECITALS 

WHEREAS, Oncogenerix is a generic and specialty pharmaceutical sales and distribution company engaged in the import, export, marketing,
sales and distribution of generic and specialty pharmaceuticals; 
 WHEREAS, Rosemont has developed and
received FDA approval of liquid tamoxifen known as “Soltamox®” for the treatment of breast cancer;

 WHEREAS, Oncogenerix is interested in obtaining an exclusive license to market, promote and sell Rosemont’s Soltamox
product in the United States of America; and 
 WHEREAS, Oncogenerix and Rosemont are entering into a Supply Agreement (the
“Supply Agreement”) and a Technical Agreement (the “Technical Agreement”) contemporaneously herewith. 
 NOW, THEREFORE, in consideration of the premises and the mutual promises and covenants set forth below, the receipt and sufficiency of which are hereby acknowledged, Oncogenerix and Rosemont mutually
agree to as follows: 
 DEFINITIONS 
 For the purposes of this Agreement, the following terms, when written with an initial capital letter, shall have the meaning ascribed to them below. All references to particular Exhibit, Articles and
Sections shall mean the Exhibits to, and Articles and Sections of, this Agreement, unless otherwise specified. 
 1.0
“Additional Territories” means any additional territories outside the Territory but excluding the United Kingdom and the Republic of Ireland in which Oncogenerix may undertake the Activities as agreed in writing between the parties
in accordance with Sections 3.l(b). 

 1.1 “Act” has the meaning set forth in Section 16.2. 

1.1 (a) “Activities” means the following activities undertaken by Oncogenerix: the use of, importation, storage, sale,
offer for sale, marketing, advertising, Promotion, detail and/or distribution. 
 1.1 (b) “Additional Products”
has the meaning set forth in Section 3.1(d) 
 1.2 [not used] 

1.3 “Adverse Event Reports” has the meaning set forth in Section 3.2. 

1.4 “Affiliates” means: 
 (a) in the case of Oncogenerix, any corporation or other business entity controlled by, controlling, or under common control with another entity, with “control” meaning direct or indirect
beneficial ownership of more than fifty percent (50%) of the voting stock of, or more than a fifty percent (50%) interest in the income of, such corporation or other business entity; or 

(b) in the case of Rosemont, means any company which is a member of the same group (as that term is defined in section 1261(1) of the
Companies Act 2006) from time to time. 
 1.4.2 “Agreement” shall mean this agreement together with the Supply
Agreement and the Technical Agreement as set out in the attached Exhibits. In the event of a conflict between the terms of this Agreement, the documents shall prevail in the following order: 

(a) main body of the Agreement; 
 (b) Exhibit B – Supply Agreement; 
 (c) Exhibit C – Commercialisation of
Licensed Products; 
 (d) Terms and Conditions of Sale; 

(e) Exhibit A – Technical Agreement. 
 1.5 “Application” means a new application, or a supplement or an amendment to an existing application, for marketing approval for a Licensed Product in the Territory. 

1.6 “Bankruptcy Code” has the meaning set forth in Section 12.4(a). 

1.7 “Breaching Party” has the meaning set forth in Section 12.4 and shall include references to the party which is
being terminated under this Agreement under Section 12. 
 1.7 (a) “Business Day” means Monday to Friday
between 9.00am and 17.00pm (GMT) excluding any public holidays in England. 

  
 2 

 1.7(b) “Claim” means: 

(i) any actual, suspected or threatened infringement of any of the Licensed Patents and/or Licensed Trademarks; 

(ii) any actual, suspected or threatened unauthorised disclosure, misappropriation or misuse of the Licensed Know-How; 

(iii) any actual or threatened claim that any of the Licensed Patents and/or Licensed Trademarks are invalid; 

(iv) any actual or threatened opposition to any of the Licensed Patents and/or Licensed Trademarks; 

(v) any claim made or threatened that exploitation of any of the Licensed Patents, Licensed Trademarks, and/or Licensed Know-How
infringes the rights of any Third Party; 
 (vi) any person applies for, or is granted, a patent by reason of which that person
may be, or has been granted, rights which conflict with any of the rights granted to Oncogenerix under this Agreement; 
 (vii)
any application is made for a compulsory licence under the Licensed Patent; and/or 
 (viii) any other form of attack, charge or
claim to which the Licensed Patents, Licensed Know-How and/or Licensed Trademarks may be subject. 
 1.8 “Commercial
Sale” means the commercial sale by way of an arm’s length transaction of a Licensed Product by Oncogenerix to a Third Party in the Territory after Regulatory Approval in the Territory, including sales of Licensed Product for use in
clinical trials and named patient sales. 
 1.9 “Competing Product” has the meaning set forth in
Section 4.5. 
 1.10 “Confidential Information” means all information (including but not limited to trade
secrets) and materials (including but not limited to data, results, technical, financial/business information or marketing strategies) disclosed by the Disclosing Party to the Receiving Party together with all information derived by the Receiving
Party from any such information and any other information clearly designated by the Disclosing Party as being confidential to it (whether or not it is marked “confidential”) or which ought reasonably be considered to be confidential.
Rosemont’s Confidential Information shall include the Licensed Know-How. 
 1.11 [not used] 

1.12 [not used] 

  
 3 

 1.13 “Cover” (including variations thereof such as “Covering” or
“Covered”) means that the manufacture, use, sale, offer for sale, or importation of a particular product would infringe a Valid Claim of a patent in the absence of rights under such patent. The determination of whether a particular product
is Covered by particular Valid Claims shall be made on a country-by-country basis. 
 1.14 “Development
Activities” means the activities undertaken as set forth in Section 3.1(a). 
 1.15 [not used] 

1.16 “Disclosing Party” has the meaning set forth in Section 13.1. 

1.17 “FDA” means the United States Food and Drug Administration and any successor agency thereto, and/or any equivalent
foreign governmental agency, depending on the context. 
 1.18 “Field” means cancer indication in humans.

 1.19 “Force Majeure Event” has the meaning ser forth in Section 16.6. 

1.20 [not used] 

1.21 “HIPAA” has the meaning set forth in Section 16.2. 

1.22 (a) “Improvements” means any and all enhancement, improvement, modification and/or developments to the Licensed
Products, Licensed Know-How and/or Licensed Trademarks (or any of them) created by either party directly, indirectly or as a consequence of this Agreement and during the Term. 
 1.22 (b) “Indemnifying Party” has the meaning set forth in Section 15.3. 
 1.22 (c) “Indemnified Party” has the meaning set forth in Section 15.3. 
 1.22 (d) “Initial Term” has the meaning set forth in Section 12.1(a). 
 1.23 “Insolvency Event” means the Breaching Party: 
 (i) has a
petition filed, a notice given, a resolution passed, or an order made, for or in connection with its winding up (other than for the sole purpose of a scheme for its solvent amalgamation with one or more other companies or its solvent reconstruction)
or such other circumstances arise which entitle a court of competent jurisdiction to make a winding-up order in respect of the Breaching Party; 
 (ii) has an application made to court, or an order made, for the appointment of an administrator, or has a notice of intention to appoint an administrator given by the Non-Breaching Party or its directors
or a qualifying floating charge holder (as defined in paragraph 14 of Schedule B1 to the Insolvency Act 1986) or has an administrator appointed over it; 

  
 4 

 (iii) has a receiver appointed over any of its assets or undertaking or circumstances arise
which entitle a court of competent jurisdiction or a creditor to appoint a receiver or manager of the Breaching Party or if any other person takes possession of or sells the Breaching Party’s assets; 

(iv) has a floating charge holder over its assets becoming entitled to appoint or has an administrative receiver appointed; 

(v) makes, or proposes to make, any arrangement or composition with its creditors or makes an application to a court of competent
jurisdiction for the protection of its creditors in any way; 
 (vi) commences negotiations with all or any class of its
creditors with a view to rescheduling any of its debts, or makes a proposal for or enters into any compromise or arrangement with its creditors (other than for the sole purpose of a scheme for its solvent amalgamation with one or more other
companies or its solvent reconstruction); 
 (vii) is, or is reasonably considered by the Non-Breaching Party giving notice to
be, unable to pay its debts when they fall due as defined in section 123 of the Insolvency Act 1986 (on the basis that the words “it is proved to the satisfaction of the court that” are deemed omitted from section 123(1)(e) and 123(2) of
that act); 
 (viii) any distraint is levied against the Breaching Party or its property by any third party; 

(ix) a creditor or encumbrancer of the Breaching Party attached or take possession of, or a distress, execution, sequestrian or other
such process is levied or enforced on or against, the whole or any part of its assets and such attachment or process is not discharged; 
 (x) the Breaching Party fails to pay any amount due under this Agreement on the due date for payment and remains in default not less than seven (7) days after being notified in writing to make such
payment; 
 (xi) the Non-Breaching Party, acting reasonably, has serious doubts as to the Breaching Party’s solvency or the
Breaching Party proposes any of the actions set out in sections (i) to (x) above; or 
 (xii) suspends or threatens to
suspend or cease, to carry on all or a substantial part of its business. 
 1.24 [not used] 

1.25 [not used] 

1.26 [not used] 

1.27 “Licensed Know-How” means the Registration Dossier, any regulatory communications and labeling relating directly to
the Licensed Product, and any Improvements 

  
 5 

 
that are owned by Rosemont as of the Effective Date or that is developed by Rosemont during the Term, and which is reasonably required for the Activities relating to the Licensed Products in the
Territory. 
 1.28 “Licensed Patent” means Rosemont’s patent known as ‘therapeutic agents containing
tamoxifen and salts thereof’, patent number 6127425, filing date 26 June 1998 and issue date of 3 October 2000 in the Territory, including any continuation, thereof. 

1.29 “Licensed Product” means Rosemont’s liquid tamoxifen product known as ‘Soltamox®’, in all dosage
forms and formulations for use in the Field. 
 1.30 “Licensed Trademarks” means Rosemont’s trademark
‘Soltamox’; registration number 3245337, registration date 22 May 2007 and expiry date 22 May 2017 together with such unregistered trademarks relating to the ‘Soltamox’ brand as are used by Rosemont in relation to the
Licensed Products in the Territory at any time during the Term. 
 1.31 “Losses” has the meaning set forth in
Section 15.1. 
 1.31 “Milestone” means the level of Net Revenues payable to Oncogenerix and in relation
to which Oncogenerix shall make a payment to Rosemont under Section 6.1(b). 
 1.32 “Net Revenues” means
the total gross sales of the Licensed Product in the Territory invoiced by Oncogenerix, its Affiliates and/or its sublicensees in any arm’s length transaction to a Third Party with respect to the sale of Licensed Product during the then-current
calendar quarter, net of, where applicable, (A) the purchase price actually paid by Oncogenerix to Rosemont for the quantities of the Licensed Product sold during the quarter in question and (B) any deductions specifically related to a Licensed
Product and actually allowed, incurred, paid or taken for any (i) VAT (or other applicable sales taxes), duties or levies, (ii) quantity or trade discounts actually granted, (iii) amounts actually repaid or credited, cash, credit or free goods
allowances given by reason of chargebacks, vendor chargebacks, patient vouchers or coupons, (iv) any price reductions imposed by courts or governmental authorities, (v) amounts refunded or credited for Licensed Product that was rejected, spoiled,
damaged, outdated or recalled, or returned, or any reasonable returned goods allowance offered in lieu of the right to return outdated Licensed Product (except to the extent that such circumstances are caused by the Third Party), (vi) actual onward
shipping costs to the extent billed directly by Oncogenerix to its customers as a separate line item on an invoice, as actually documented by actual invoices. If Oncogenerix, its Affiliates or sublicensees receive non-cash consideration for Licensed
Product sold or otherwise transferred (in any event excluding any Promotional Materials) to a Third Party, the fair market value of such non-cash consideration on the date of the transfer as known to Oncogenerix, or as reasonably estimated by
Oncogenerix if unknown, shall be included in Net Revenues for such Licensed Product sold or otherwise transferred. Where the Licensed Product is: 
 (a) supplied other than in an arm’s length transaction; 
 (b) sold or
otherwise supplied to any of Oncogenerix’s Affiliates; 
 (c) incorporated into another article and sold or otherwise
supplied at a price which is included in the price of the other article; or 
 (d) put into use by Oncogenerix; 

the Net Revenues of each such Licensed Product shall be deemed to be the Net Revenue which would have been applied under this Agreement
had such Licensed Product been transferred to an independent arm’s length customer. 
 If a Licensed Product is sold or
offered for sale in combination with other products of Oncogenerix at a price that is reduced or discounted from the normal selling price (the “Discounted Bulk Purchase”) of Oncogenerix for such Licensed Product and if that discount is
only available with or is conditioned upon the purchase of such other products, the Net Revenues determined as provided for in this Section 1.32 shall be adjusted as if the discount or reduction had been applied to all products of such
combination equally. “Non-Breaching Party” has the meaning set forth in Section 12.4 and shall include references to the party that exercises its right to terminate this Agreement under Section 12. 

  
 6 

 1.33 [not used] 
 1.34 “Oncogenerix Data” has the meaning set forth in Section 3.1(e). 
 1.35 “Prescriber Data” shall mean data which measures prescriptions written for the Licensed Product in the Territory during a specified time period from a source mutually agreed in
writing by the parties. 
 1.36 “Promotion” means those activities normally undertaken by a pharmaceutical
company to implement promotion plans and strategies aimed at encouraging the appropriate use of a particular prescription pharmaceutical product under a common trademark, up to the point of offering the product for sale. When used as a verb,
“Promote” shall mean to engage in such activities. 
 1.37 “Promotional Materials” has the
meaning set forth in Section 9.4. 
 1.38 [not used] 

1.39 [not used] 

1.40 “Reasonable Diligence” means using all reasonable endeavours consistent with those used by pharmaceutical companies
similarly situated to Oncogenerix or Rosemont (as the case may be) in activities that are the same as or similar to the Activities in respect of other pharmaceutical products similarly situated to the Licensed Product. 

1.41 “Receiving Party” has the meaning set forth in Section 13.1. 

1.42 “Regulatory Approval” means, with respect to the United States, the final approval of a 505b-2 or 505j-2
Abbreviated New Drug Application (“ANDA”) by the FDA, and, with respect to other jurisdictions, the final approval of the foreign equivalent to a ANDA, and the granting of all other governmental regulatory approvals required
(including pricing reimbursement), if any, for the sale of a Licensed Product in a given country or jurisdiction. 
 1.43 (a)
“Registration Dossier” means all written pertinent and necessary information in such detail as currently requested by the FDA in order to grant authorization for sale and marketing of the Licensed Product and including all technical
and scientific information in written form, acquired and/or developed by Rosemont relating to active ingredients of the Licensed Product; 
 1.44 (b) “Renewal Term” has the meaning ascribed to it in Section 12.1(b). 
 1.44 “Rosemont” means Rosemont Pharmaceuticals Limited (company number: 00924648) only. 
 1.45 (a) “Royalties” means the sums payable by Oncogenerix to Rosemont pursuant to Section 6.1. 
 1.45 “Oncogenerix Know-How” has the meaning set forth in Section 8.4. 

  
 7 

 1.46 “Oncogenerix Trade Dress” has the meaning set forth in
Section 9.2. 
 1.47 (a) “Regulatory Costs” has the meaning set forth in Section 3.1(a). 

1.47 “Supply Agreement” has the meaning set forth in Section 5.1. 

1.48 “Tail Period” has the meaning set forth in Section 12.9(b). 

1.49 “Territory” means the United States of America, including its territories and possessions together with any
Additional Territories as agreed between the parties pursuant to Section 3.1(b) from time to time. 
 1.50
“Term” means the Initial Term and the Renewal Term (as appropriate). 
 1.51 “Third Party”
means any person or entity including any Affiliates, but excluding Oncogenerix or Rosemont. 
 1.52 “Valid
Claim” means a claim in any issued patent that has not been disclaimed, abandoned, denied or admitted to be invalid or unenforceable through reissue or disclaimer or otherwise, or held permanently revoked unenforceable or invalid by a
decision of a court or governmental agency of competent jurisdiction by a decision beyond right of review. 
 1.54
“Year” means the twelve (12) month period commencing on the Effective Date and each consecutive twelve (12) month period thereafter during the Term. 
 II. GRANT OF RIGHTS 
 2.1 Grants to Oncogenerix. 

(a) Patent and Know-How License. Subject to the terms and conditions of this Agreement, Rosemont grants to Oncogenerix, during the
Term, the exclusive (even as to Rosemont and its Affiliates) right and license, with the right to subcontract and sublicense, under the Licensed Know-How and Licensed Patents, to undertake the Activities in respect of the Licensed Product in the
Territory solely for use in the Field. For the avoidance of doubt, Rosemont (and/or its Affiliates) shall retain the right to use the Licensed Know-How and Licensed Patents to manufacture and export the Licensed Products on a worldwide basis.

 (b) Trademark License. Subject to the terms and conditions of this Agreement, Rosemont grants to Oncogenerix, during
the Term, the exclusive right and license, with the right to subcontract and sublicense, to use the Licensed Trademark(s), solely in connection with the Activities in respect of the Licensed Product in the Territory for use in the Field. Oncogenerix
acknowledges and agrees that all of its (including its Affiliates and sublicensees) use of the Licensed Trademark(s) and any and all goodwill arising as a result of the Activities relating to the Licensed Products in the Territory shall inure to the
benefit of Rosemont (and/or its Affiliates), and that Oncogenerix shall not acquire any ownership rights in and to the Licensed Trademark(s) by virtue of its uses of the Licensed Trademarks under this Agreement. 

  
 8 

 (c) Right to Sublicense. Oncogenerix may sublicense its rights and licenses granted
under Sections 2.1(a) and 2.1(b) to a Third Party only with Rosemont’s express prior written consent. Oncogenerix shall procure that its permitted sub-licensees who are at any time associated with, engaged in, connected with this Agreement
shall comply with the terms and conditions of this Agreement as though original parties to this Agreement. Oncogenerix shall procure that the contracts with its sublicensees contains a provision as to allow the assignment of such sublicensee
contract to Rosemont in the event that Rosemont terminates this Agreement for any reason whatsoever. If Oncogenerix sublicenses its rights and licenses or appoints a sub-contractor under this Agreement, Oncogenerix shall nevertheless continue to be
liable for the performance of its obligations under this Agreement, and shall be fully responsible for the actions of its sublicensees and/or appointed sub-contractors and shall indemnify and keep indemnified Rosemont (and/or its Affiliates) against
any and all Losses arising as a result of any act, omission, breach and/or negligence of such sublicensees. 
 2.2 [not used]

 III. DEVELOPMENT; REGULATORY ISSUES 
 3.1 Development. 
 (a) Regulatory Approval in the Field. The parties
acknowledge that the Licensed Product has previously received Regulatory Approval in the Territory for use in breast cancer treatment in humans. Oncogenerix and/or its Affiliates shall be responsible for carrying out any procedures necessary to
confirm, revive or otherwise perfect the Regulatory Approval for Commercial Sale of the Licensed Product in the Field in the Territory (“Development Activities”). Oncogenerix shall provide written notice to Rosemont of any
reasonable costs contemplated to be incurred by Oncogenerix over and above US$20,000 (twenty thousand US dollars), directly in furtherance of perfecting the Regulatory Approval of the Licensed Product in the Territory (“Regulatory
Costs”) prior to incurring such Regulatory Costs and, provided that Rosemont has approved such Regulatory Costs (or such Regulatory Costs are less than US$20,000 (twenty thousand US dollars)), Oncogenerix may deduct the Regulatory Costs
from the Royalties payable by Oncogenerix to Rosemont. Oncogenerix shall deduct fifteen percent (15%) from each quarterly Royalty payment until Oncogenerix has been reimbursed for such Regulatory Costs. Oncogenerix shall provide to Rosemont
documentary evidence to support any claim for Regulatory Costs together with the relevant Royalty payment from which the deduction has been made. 
 (b) Additional Territories. Oncogenerix may make a written request to Rosemont to extend the Activities relating to the Licensed Product into Additional Territories. Rosemont will consider in good
faith such a request but shall not be obliged to agree to the inclusion of any Additional Territories. Any agreement between the Parties regarding Additional Territories shall be made in accordance with Section 16.5. 

(c) [not used] 

(d) Other Development-Additional Products. Rosemont and/or its Affiliates: (i) at their sole discretion and their sole cost
and expense, may develop liquid pharmaceutical products other than the Licensed Product for any indication, whether inside the Field or not, and; 

  
 9 

 
(ii) has developed liquid pharmaceutical products other than the Licensed Product which have previously received Regulatory Approval, examples of which are set out in Exhibit D (each
“Additional Products”). In the event Rosemont successfully develops and obtains Regulatory Approval for any Additional Products pursuant to this Section 3(d) and within the Territory, Oncogenerix may make a written request to
Rosemont to undertake the Activities in respect of the Additional Products within the Territory. Rosemont shall consider in good faith such a request but shall not be obliged to agree to permit Oncogenerix to undertake the Activities in respect of
the Additional Products within the Territory. Any agreement between the parties regarding the Additional Products shall be the subject of a separate agreement between the Parties. 

(e) Ownership of Data and Regulatory Approvals. Except as otherwise set forth in this Agreement, all data and information
generated by any Development Activities pursuant to this Section 3.1 shall be owned by Rosemont and/or its Affiliates and shall be deemed Licensed Know-How. Rosemont and/or its Affiliates shall hold and own all Regulatory Approvals. Rosemont
grants to Oncogenerix the sole and exclusive right to market the Licensed Product under Rosemont’s and/or its Affiliates’ Regulatory Approvals in the Field in the Territory. Oncogenerix shall hold and own all Prescriber Data, marketing,
sales, distribution and other commercialization data and other marketing, sales, distribution and commercialization information resulting from the Activities regarding the Licensed Product undertaken by Oncogenerix (and/or its Affiliates and
sublicensees) in the Field in the Territory following the Effective Date (together referred to as “Oncogenerix Data”). Upon request, Oncogenerix shall make available to Rosemont any and all Oncogenerix Data within Oncogenerix’s
(or Oncogenerix’s Affiliates’ and/or sublicensees’) possession or control that Rosemont may need to comply with FDA reporting requirements and other regulations; Oncogenerix shall provide copies of any documents, in electronic or
paper form as requested by Rosemont, within five (5) business days of Rosemont’s request. 
 3.2 Adverse Event
Reporting. 
 (a) Oncogenerix and Rosemont shall notify each other of all information coming into its respective possession
concerning any and all adverse events relating to the Licensed Products as detailed under the Technical Agreement (“Adverse Event Reports”) as provided in the Technical Agreement, in substantially the form attached hereto as Exhibit
A. Each party agrees to share relevant information it receives (either directly or indirectly) with the other party in a timely manner and in any event in accordance with all applicable laws and regulations so as to allow such other party to comply
with its responsibility to process pharmacovigilance information under this Section 3.2 and any applicable laws and regulations. Each party also agrees to report such information to the FDA or EU equivalent in any country required in a timely
manner, and in no event later than the prescribed period of time for reporting such information. 
 (b) For the avoidance of
doubt, Oncogenerix shall have the responsibility of filing the annual report for the Licensed Product with the FDA in the Territory and Rosemont shall provide Oncogenerix on a timely basis with any such information which shall be necessary for
Oncogenerix to comply with the requirements of this section. Oncogenerix shall indemnify and keep indemnified Rosemont (and/or its Affiliates) against any and all Losses resulting from Oncogenerix’s failure to comply with the provisions of this
Section 3.2(b) to the extent that such 

  
 10 

 
Losses were not incurred as a direct result of Rosemont’s failure to comply with the information provision under this Section 3.2(b). Except as specifically provided in this
Section 3.2(b), Rosemont shall have the responsibility of filing all regulatory reports with respect to the Licensed Product. 
 IV. COMMERCIALIZATION; MANAGEMENT 
 4.1 Commercialization.

 (a) By Oncogenerix. During the Term and in the Territory, Oncogenerix shall use Reasonable Diligence, at its sole cost
and expense, and in such a manner as Oncogenerix may in its reasonable discretion determine reasonable and appropriate, for: 

(i) the marketing and sale of Licensed Product in the Field; 
 (ii) accepting and fulfilling orders for Licensed Product received by it and/or its Affiliates from customers in the Field, including the distribution of Licensed Product to fulfill such orders (provided
that Rosemont shall inform and transfer to Oncogenerix any and all active orders it and/or its Affiliates receive for Licensed Products in the Territory); 
 (iii) booking all sales and reimbursement obligations of Licensed Product attributable to such orders; 
 (iv) establishing and managing reimbursement strategies within the Territory; 

(v) warehousing and distribution of Licensed Product within the Territory; 

(vi) establishing and managing field sales and sales operations, and performing visits to, national accounts, including managed care,
trade and government accounts; 
 (vii) responding to medical questions or enquiries from members of the medical and
paramedical professions and consumers regarding Licensed Product, including the distribution of standard medical information letters resulting from the marketing activities of Oncogenerix’s sales representatives; 

(viii) performing market research in connection with Licensed Product; and 

(ix) any other activities reasonably related to the Activities regarding the Licensed Product, including the handling/processing of
returns, refunds, rebates and wholesaler charge-backs and administration of managed care contracts, federal and state government contracts, rebate contracts, long-term care contracts, performance-based contracts and hospital purchasing contracts.

 (x) making clear, in all dealings with customers and prospective customers, that it is acting as an authorized distributor
of the Licensed Products and not as agent of Rosemont; 
 (xi) beginning six (6) months from the date of the first
Commercial Sale of the Licensed Product by Oncogenerix in the Territory, maintaining an active and suitably trained sales force and being fully responsible for all selling and sales support activities in the Territory; 

  
 11 

 (b) By Rosemont. During the Term and in the Territory, Rosemont shall use reasonable
endeavours, at its sole cost and expense (subject to the proviso set out below), for: 
 subject to
Section 3.2(b), regulatory affairs related to Regulatory Approvals and regulatory maintenance-related matters within the Territory; 
 manufacturing and supply of the clinical supplies of Licensed Product necessary for the bio-equivalency and clinical studies, if any, necessary for Regulatory Approval within the Territory; 

manufacturing of commercial supply quantities of Licensed Product within the Territory pursuant to the Supply Agreement;
and 
 any other activities reasonably related to the development, registration, manufacturing or supply of
Licensed Product mutually agreed to by the parties. 
 4.2 Compliance with Law. Oncogenerix shall comply with all legal
requirements applicable to the Activities relating to the Licensed Product in the Territory, including, without limitation, any applicable statutory or regulatory requirements relating to the Promotional Materials for the Licensed Product in the
Territory. Rosemont shall maintain responsibility for labeling compliance and maintenance relating to the Licensed Product, and notify Oncogenerix of any changes to labeling at the time of FDA approval thereof; and Oncogenerix shall seek
Rosemont’s written approval prior to adopting or changing any packaging or labeling for the Licensed Product. 
 4.3
Promotional Materials. Oncogenerix shall provide samples of Promotional Materials to Rosemont not less than ten (10) days prior to the time of first using or distributing such Promotional Materials in the Territory and shall obtain
Rosemont’s written approval before 
 using or distributing such Promotional Material; such approval not to be unreasonably delayed,
conditioned or denied. Rosemont will approve the Promotional Materials within five (5) business days of receipt of such Promotional Materials from Oncogenerix. If Rosemont does not provide its approval or notice that it does not approve the
Promotional Materials within the timescale in this Section 4.3, the Promotional Materials will be deemed to be approved. Oncogenerix will use Reasonable Diligence to make such amendments to the Promotional Materials as requested by Rosemont
under this Section 4.3. Oncogenerix shall own all right, title and interest in and to any Promotional Materials created by Oncogenerix relating to the Licensed Products, but excluding the Licensed Trademark(s); provided that, the Promotional
Materials shall be used exclusively in connection with the Licensed Products in accordance with the terms of this Agreement. Where required by law, Oncogenerix shall submit Promotional Materials to the FDA (DDMAC) for review and approval. In the
event that the FDA issues a letter objecting to any Promotional activities by Oncogenerix that require corrective actions (e.g. issuance of Dear Healthcare Professional letters, recall of Promotional Materials and/or dissemination of corrected
Promotional Material), Oncogenerix will bear all the cost related to these corrective activities except to the extent that any such costs are caused by changes requested by Rosemont, in which case Rosemont shall bear the costs of such corrective
activities. 

  
 12 

 4.4 Pricing. As between the parties, Oncogenerix has the sole right to determine the
price for Licensed Product within the Territory, subject to appropriate governmental rules and regulations, where applicable. 

4.5 Non-Compete. During the Term, Oncogenerix shall not undertake any Activities in respect of any oral liquid pharmaceutical
product for treatment of cancer in a competitive indication in humans (a “Competing Product”) in the Territory. Notwithstanding the above, but subject to Section 16.4(a), Oncogenerix is not precluded from entering into a merger
or acquisition of or with an entity that markets, distributes, Promotes, details or sells a Competing Product in the Territory, provided that consolidated revenues from a Competing Product constitute less than 25% of such entity’s consolidated
revenues. In the event Oncogenerix enters into a merger with or acquisition of an entity whose consolidated revenues from a Competing Product are equal to or greater than 25% of such entity’s consolidated revenues, then Oncogenerix will use
reasonable commercial efforts to sell that portion of the entity’s business engaged in the marketing, distribution, Promotion, detailing or selling of Competing Product during the period of time covered by this Section 4.5. 

4.6 Oncogenerix shall comply with the terms and conditions set out in Exhibit C in performing the Activities relating to the Licensed
Products in the Territory. 
 V. MANUFACTURING 

5.1 Commercial Supply. Rosemont shall supply to Oncogenerix all its requirements for Licensed Product (including samples and
clinical supplies), subject to Oncogenerix’s obligation to make Royalty payments in accordance with Section VI. As part of this Agreement, Rosemont and Oncogenerix shall comply with the terms and conditions of the supply agreement, as detailed
in Exhibit B (the “Supply Agreement”), governing the commercial supply of Licensed Product (including samples and clinical supplies) by Rosemont to Oncogenerix (including the procedures for providing forecasts of Oncogenerix’s
requirements, for ordering Licensed Product, and for return and replacement of Licensed Product that does not meet product specifications). For purposes of clarity, all Licensed Product (other than samples and clinical supplies) supplied by Rosemont
to Oncogenerix hereunder shall be in finished form and packaged in primary packaging, ready to sell. 
 VI. PAYMENTS

 6.1 Royalties. (a) During the Term, Oncogenerix shall pay Rosemont quarterly Royalties equal to five
(5%) per cent of Oncogenerix’s Net Revenues of the Licensed Product. All Royalty payments shall be due within thirty (30) days after the close of each calendar quarter. 

(b) Milestones. During the term of this Agreement, Oncogenerix shall pay to Rosemont the following Milestone payments within
thirty (30) days of the relevant Milestone being met by Oncogenerix: 
  

					
	 Milestone based on
 Oncogenerix’s Net Revenues
	  	Milestone
Payment – 
US$	 
	 US$5,000,000
	  	US$	250,000	  
	 US$10,000,000
	  	US$	500,000	  
	 US$15,000,000
	  	US$	750,000	  
	 US$20,000,000
	  	US$	1,000,000	  

  
 13 

 6.2 Payments on Termination. If this Agreement is terminated, Oncogenerix shall
continue to be responsible for payment of all amounts accrued under this Agreement and/or the Supply Agreement prior to the date of termination (including any Royalty or Milestone payments). Any such amounts shall be due and payable within thirty
(30) days after termination. If Oncogenerix is permitted to sell its inventory of Licensed Product pursuant to Section 12.10, then Oncogenerix shall pay to Rosemont any Royalties and Milestone payments pursuant to Section 6.1 achieved
after termination (during the Tail Period). Such payments shall be paid within thirty (30) days after the end of the calendar quarter during which such sales were made or thirty (30) days after the date on which such Milestone was
achieved. 
 6.3 Sublicenses. Any Net Revenues or gross sales by an Oncogenerix sublicensee shall be treated as Net
Revenues and gross sales, respectively, of Oncogenerix, for the purposes of payments under this Article VI. If Oncogenerix grants any sublicenses under this Agreement, then Oncogenerix shall obtain the written commitment of such sublicensees to
abide by all applicable terms and conditions of this Agreement, but Oncogenerix shall remain responsible to Rosemont for the performance by such sublicensee of any and all terms in accordance with Section 2.1(c). 

6.4 Interest. In the event that Oncogenerix is late in paying to Rosemont any amounts due under this Section VI within the
applicable time period set forth herein, such payment shall bear interest (both before and after judgment) at the average one-month London Interbank Offered Rate (LIBOR) as reported by Datastream (or a successor or similar organization) from time to
time, such interest to accrue on a daily basis from the due date for payment until receipt of payment in full and cleared funds by Rosemont. 
 VII. PAYMENTS, REPORTS, AND ACCOUNTING 
 7.1 Royalty Payments and
Reports. Oncogenerix agrees to make payments within thirty (30) days after the end of each calendar quarter covering all Commercial Sales of, and Net Revenues from, the Licensed Product in the Territory by Oncogenerix, its Affiliates and/or
sublicensees for which invoices were issued during such calendar quarter. Oncogenerix agrees to provide written reports to Rosemont within thirty (30) days after the end of each calendar quarter detailing all Commercial Sales of Licensed
Product in the Territory by Oncogenerix for which invoices were sent during such calendar quarter. Each report shall state for the period in question: 
 (a) for Licensed Product disposed of by Commercial Sale, the gross sales of Licensed Product, and the detailed calculation of Net Revenues; 

(b) for Licensed Product disposed of other than by Commercial Sale, the quantity, description, and nature of the disposition; and

 (c) the calculation of the amount due to Rosemont for such quarter pursuant to Article VI. 

7.2 Accounting. Oncogenerix agrees to keep full, clear, true, accurate and up-to-date records for a period of at least three
(3) years, setting forth the Commercial Sales and other disposition of Licensed Product and Net Revenues in sufficient detail to enable Royalties and compensation payable to Rosemont hereunder to be determined. 

  
 14 

 7.3 Audit. Oncogenerix further agrees to permit its books and records to be examined
by a nationally recognized independent certified public accounting firm selected by Rosemont and retained for the purpose of auditing the same at Rosemont’s expense to verify records provided for in this Article VII and the Royalties payable
under Article VI. Such audit shall be conducted for the purpose of verifying the accuracy of reports delivered by Oncogenerix to Rosemont pursuant to Sections 7.1 and 7.2 and the accuracy of Oncogenerix’s determination of the amounts payable or
paid by Oncogenerix to Rosemont under this Agreement and/or the Supply Agreement. Such audit shall not be performed more frequently than once per calendar year nor more than once with respect to the records covering any specific period of time. Such
examination is to be made at the expense of Rosemont, except in the event that the results of the audit reveal a discrepancy in favor of Oncogenerix of five percent (5%) or more of Net Revenues over the period being audited, in which case the audit
fees for such examination shall be paid by Oncogenerix. Oncogenerix shall pay to Rosemont within thirty (30) days after the delivery of the accountant’s report pursuant to this Section 7.3 all amounts plus interest payable under
Section 6.4 above and/or under the Supply Agreement determined by the accountant to be payable by Oncogenerix to Rosemont. If the accountant determines that Oncogenerix has overpaid Rosemont, Rosemont shall, at the election of Oncogenerix,
credit Oncogenerix in an amount equal to such overpayment on the immediately succeeding invoice rendered to Oncogenerix, or pay Oncogenerix such amount within thirty (30) days after receipt of an invoice therefor. 

7.4 Methods of Payments. All payments due under this Agreement shall be paid in United States dollars (US$) by BACS transfer to a
bank in England designated in writing by Rosemont. 
 7.5 Taxes. Royalties and other sums payable under this Agreement
are exclusive of VAT (or similar tax) and shall be paid free and clear of all deductions and withholdings whatsoever, unless the deduction or withholding is required by law. If Oncogenerix is required by law to make a deduction or withholding,
Oncogenerix will, within five (5) business days of making the deduction or withholding, provide a statement in writing showing the gross amount of the payment, the amount of the sum deducted and the actual amount paid. 

7.6 Royalties shall be payable under this Agreement even if some part of the Activities relating to the Licensed Products undertaken by
Oncogenerix takes place in a part of the Territory (or Additional Territories) where there is no Licensed Patent or where the Licensed Product does not fall within the scope of the Licensed Patent. 

VIII. OWNERSHIP OF TECHNOLOGY AND INTELLECTUAL PROPERTY 

8.1 Ownership. Subject to Section 10.1 only, ownership of any Licensed Know-How and/or Licensed Patents improved, modified,
developed or created during the Term shall remain vested at all times in Rosemont and Oncogenerix hereby assigns as a present and immediate assignment of future rights all such right and title to Rosemont; upon such assignment, Rosemont shall grant
Oncogenerix, for no additional consideration, the right to use such improvement, 

  
 15 

 
modification, development or creation related to the Licensed Know-How and/or Licensed Patents for the duration of the Term and any Renewal Term. Rosemont expressly reserves under this Agreement
all rights to use the Licensed Know-How, the Licensed Patents, and any other Rosemont patents to make, have made, use, export, undertake the Activities in respect of the Licensed Product outside of the Territory and to make, have made, use and
export the Licensed Product within the Territory. 
 8.2 Rosemont Inventions. As between the parties, Rosemont shall own
any and all inventions invented, either solely or jointly with Third Parties, by the employees or agents of Rosemont, and any patents Covering such inventions. 
 8.3 [not used] 
 8.4 Oncogenerix Technology. If during the Term,
Oncogenerix develops any know-how relating to the use, manufacture, and/or undertaking of the Activities relating to the Licensed Product (the “Oncogenerix Know-How”), Oncogenerix shall immediately grant a non-exclusive,
non-royalty-bearing, perpetual, irrevocable, worldwide, transferable license to Rosemont to use the Oncogenerix Know-How. 

IX. Trademarks. 
 9.1 Ownership. 
 (a) Rosemont shall exclusively own any Licensed Trademarks
created during the Term, and shall retain the right to use the Licensed Trademarks in the Territory in connection with the Activities relating to any products other than the Licensed Product. Rosemont shall also retain the right to use the Licensed
Trademark(s) in connection with the Activities relating to the Licensed Product outside the Field within the Territory and/or outside the Territory. Oncogenerix shall have no right to use the Licensed Trademark(s), or any other marks confusingly
similar to the Licensed Trademark(s), in connection with the Activities relating to any product other than the Licensed Product. 
 (b) Except as provided in Section 2.1, Oncogenerix shall have no rights in respect of any trade names or Licensed Trademarks or the other intellectual property rights used by the Rosemont and/or its
Affiliates in relation to the Licensed Products or of the goodwill associated therewith, and Oncogenerix hereby acknowledges that, except as expressly provided in this Agreement, it shall not acquire any rights in respect thereof. 

(c) Oncogenerix shall, at Rosemont’s expense, take all such steps as Rosemont may reasonably require to assist Rosemont in
maintaining the validity and enforceability of the Licensed Trademarks and/or the Licensed Patents during the continuance of this Agreement. 
 (d) Without prejudice to the right of Oncogenerix or any third party to challenge the validity of any Licensed Trademarks or Licensed Patents, Oncogenerix shall not do or authorize any third party to do
any act which would or might invalidate or be inconsistent with the Licensed Trademarks and/or Licensed Patents or omit to do any act which, by its omission, would have that effect or character. 

  
 16 

 (e) Oncogenerix shall not: 

(i) alter, remove or tamper with any Licensed Trademarks and/or Licensed Patents numbers, or other means of identification used on or in
relation to the Licensed Products; 
 (ii) use any of the Licensed Trademarks in any way which might prejudice their
distinctiveness or validity or the goodwill of Rosemont (and/or its Affiliates); 
 (iii) use in relation to the Licensed
Products any trademarks other than the Licensed Trademarks and the Oncogenerix Trade Dress without obtaining the prior written consent of Rosemont; or 
 (iv) use any trademarks or trade names so resembling any Licensed Trademarks or trade names of Rosemont (and/or its Affiliates) as to be likely to cause confusion or deception; or 

(v) make an application to or actually register the unregistered Licensed Trademarks in the Territory without Rosemont’s prior
written consent. 
 9.2 Trade Dress. Notwithstanding the foregoing, as soon as reasonably practicable prior to or upon
Rosemont’s application for Regulatory Approval, Oncogenerix shall prepare and submit to Rosemont a sample of Oncogenerix’s trade dress to be utilized to distribute the Licensed Products in the Territory (the “Oncogenerix Trade
Dress”) which shall be in accordance with all applicable laws. Oncogenerix hereby grants to Rosemont the right to use, with the right to grant Rosemont’s Affiliates the right to use, such Oncogenerix Trade Dress in the Territory solely
for the purpose of performing its obligations under this Agreement, the Technical Agreement and/or the Supply Agreement. Oncogenerix shall own and retain all rights to the Oncogenerix Trade Dress and all goodwill associated therewith. The
Oncogenerix Trade Dress shall be used only pursuant to the terms of this Agreement to identify, and in connection with, the distribution of the Licensed Products in the Territory, and shall not be used by either party to identify, or in connection
with, the marketing of any other products. Except as otherwise set forth in this Agreement, Rosemont’s (and/or its Affiliates’) right to use the Oncogenerix Trade Dress shall automatically terminate upon the termination or expiration of
this Agreement. 
 9.3 Selection, Prosecution and Maintenance. The parties acknowledge that Rosemont has registered the
trademark “Soltamox” for the Licensed Product in the USA. With respect to any Additional Territories, any necessary trademark applications and registrations shall be deemed to be Licensed Trademarks. Rosemont shall be responsible for, and
have full control over, the filing, prosecution and maintenance of and, subject to Section 10, any infringement actions relating to the Licensed Trademark(s). 
 9.4 Quality Control. Rosemont shall exercise full control with respect to the nature and quality of the Licensed Product and shall be entitled to approve any and all advertising and promotional
materials used in connection with the Licensed Product, including such materials bearing the Licensed Trademark(s) (“Promotional Materials”) as set forth in Section 4.3. Oncogenerix acknowledges that the Licensed Trademarks and
Rosemont’s other trademarks have established valuable goodwill and are well recognized in the minds of the relevant class of 

  
 17 

 
customers, and Oncogenerix agrees that the Promotional Material and any Activities relating to the Licensed Products shall be equal to the standard of quality heretofore established and
maintained by Rosemont and its Affiliates in the operation of its business. 
 (a) At Rosemont’s request, Oncogenerix
shall: (i) provide specimens of Licensed Product, Promotional Materials and other materials reasonably sufficient to enable Rosemont to further monitor the quality of Licensed Product and/or Promotional Materials offered by Oncogenerix in
connection with the Licensed Trademark(s); and (ii) permit Rosemont (and/or its authorized representatives) to inspect, during regular business hours and on reasonable prior written request, the portions of the premises and facilities (except
with respect to current Third Party subcontractors, in such case Oncogenerix shall only be required to use Reasonable Diligence to cause such Third Party to allow such inspection) where the Licensed Products will be stored under the Licensed
Trademark(s). 
 (b) Oncogenerix agrees to use Reasonable Diligence to comply with applicable laws and regulations relating to
the use of the Licensed Trademark(s), including, but not limited to, those laws and regulations which require Oncogenerix to indicate that it is a licensee of the Licensed Trademark(s), that Rosemont owns the Licensed Trademark(s) and/or that
Rosemont is the source of the products and/or services sold thereunder. 
 (c) Oncogenerix shall use Reasonable Diligence to
comply with all applicable international, federal, state and local laws, regulations, standards, statutes and guidelines, and obtain all foreign and domestic government approvals, pertaining to the Activities relating to the Licensed Products in the
Territory. 
 (d) Oncogenerix shall not, by any act or omission, tarnish, disparage, degrade, dilute or injure the reputation of
the Licensed Trademark(s) owned by Rosemont or its Affiliates and/or the goodwill associated therewith. 
 9.5 Trademark
Marking. Oncogenerix shall ensure that each reference to and use of any Licensed Trademarks by Oncogenerix is in a manner approved by Rosemont in accordance with the terms of this Agreement. If requested by Rosemont, Oncogenerix shall use the
initials “TM” (or TM) in association with the Licensed Trademark(s), until such time as Oncogenerix is informed that a form of the Licensed Trademark(s) has been registered for any one or more of the Licensed Products. Oncogenerix
shall use the notation ® in association with each such registered form of the Licensed Trademark(s) in respect of the Promotional Materials and/or the Licensed Products. 
 9.6 Trademark Legend. To the extent practicable based on the nature and size of the Promotional Material in question, Oncogenerix shall place on all Promotional Materials which show the Licensed
Trademark(s), including product packaging, the legend “The trademarks [list relevant trademarks] are owned by Rosemont Pharmaceuticals Ltd and are licensed by Oncogenerix, Inc.” 

  
 18 

 X. PATENT PROSECUTION – NOT USED 

10.1 Improvements 
 (a) Oncogenerix accepts and confirms that all work done by it in connection with the Licensed Products and/or the development of the Licensed Products during the continuance of this Agreement shall accrue
for the benefit of Rosemont. If at any time Oncogenerix makes or discovers any Improvement in the Licensed Products (or any of them) then Oncogenerix shall, to the extent that it is not prohibited by law, assign such Improvement to Rosemont pursuant
to Section 8.1. 
 (b) Oncogenerix shall communicate in writing to Rosemont full details and particulars of an Improvement
made by it in relation to the Licensed Products during the continuance of this Agreement together with all necessary materials, samples, documents, data, information, and at the request of Rosemont it shall assist Rosemont (and/or its Affiliates) in
applying for and obtaining a patent or other monopoly protection as appropriate for such Improvement, and it shall, at the request and cost of Rosemont, do and execute all such acts, deeds, matters and things as may be necessary to apply for and
obtain such protection in any part of the world. 
 (c) Information provided by Oncogenerix to Rosemont under Section 10.1
shall constitute Confidential Information and be subject to the provisions of Section XIII. 
 XI. ENFORCEMENT AND DEFENSE
OF PATENTS 
 11.1 Enforcement of Patent Rights/Trademarks. 

(a) Notice. If either party becomes aware of any Claim then that party shall give prompt written notice to the other party within
five (5) business days after gaining knowledge of such infringement or violation. 
 (b) Rosemont’s Primary Right
to Bring Action. 
  

	 	(i)	Rosemont shall have the primary right in its absolute discretion, but not the obligation, to institute, prosecute and/or control any action or proceeding, with respect
to such Claims, by legal counsel of its own choice. If Rosemont institutes such an action, on Rosemont’s reasonable request, Oncogenerix shall have the right (but not the obligation), to agree to be joined as a party to the litigation if it is
necessary or strategically advantageous (as determined by the parties in consultation with their respective patent litigation counsel) for Oncogenerix to be included as a party. Oncogenerix shall bear its own costs if it is joined as a party to the
litigation. 

  

	 	(ii)	Oncogenerix shall not make any admissions relating to any Claim other than to Rosemont and shall provide Rosemont with all assistance that it may reasonably require in
the conduct of any Claim. 

 (c) Allocation of Recovery. Any damages or monetary awards (including any
settlement payments) recovered by Rosemont shall be retained by Rosemont for its own account. 
 (d) [not used]

  
 19 

 (e) Right to Counsel. In any event, Oncogenerix shall have the right to be
represented by counsel of its own choice in respect of any Claim under Section 11.1(b). 
 11.2 [not used]

 11.3 [not used] 
 11.4 [not used] 
 11.5 The provisions of section 67(i) of the Patents Act
1977 (or equivalent legislation in any jurisdiction) are expressly excluded. 
 XII. TERM AND TERMINATION

 12.1 Initial Term. (a) Unless earlier terminated pursuant to the terms of this Article XII, this Agreement
shall be effective on the Effective Date and shall continue until the later of: (i) seven (7) years from the Effective Date; or (ii) the expiry of the last-to-expire Licensed Patent, if any, Covering the Licensed Product in the Territory.
The period of time from the Effective Date until the date of expiration or termination under this Section 12.1(a) shall be referred to as the “Initial Term”. 

(b) Renewal Term. The Initial Term shall automatically extend for successive periods of one (1) year (“Renewal
Term”), unless either Party notifies the other Party in writing at least twelve (12) months prior to the expiry of the Initial Term or the relevant and applicable Renewal Term that the Party does not wish the first or successive
Renewal Term to apply. 
 12.2 Termination for Interruption of Regulatory Approvals. Either party shall have the right to
terminate this Agreement on reasonable written notice to the other party if the Regulatory Approval in the Territory is withdrawn. 
 12.3 Termination for Breach. Each non-breaching party (the “Non-Breaching Party”) shall be entitled to terminate this Agreement by written notice to the other party (the
“Breaching Party”) in the event that the Breaching Party is in (i) material breach, (ii) persistent or repeated breach, and/or (iii) breach of a material term (including Section 9.4(d)), of this Agreement, the
Technical Agreement and/or under the Supply Agreement and fails to remedy such breach within thirty (30) days (or, in the case of payment defaults, within seven (7) days) after provision of written notice thereof by the Non-Breaching
Party. The effective date of termination under this Section 12.4 for an unremedied material breach shall be the date thirty (30) days (or, in the case of an unremedied payment default, seven (7) days) after provision of written notice
thereof by the Non-Breaching Party. 
 12.4 Termination for Insolvency. Either party may terminate this Agreement upon
written notice to the other party (with such termination effective upon receipt of such written notice) for an Insolvency Event. For the avoidance of doubt, an Insolvency Event shall include anything analogous to an Insolvency Event in any relevant
jurisdiction, including in the Territory. Such analogous Insolvency Events shall include if: 
 (a) Oncogenerix commences a
voluntary case under the United States Bankruptcy Code, as now or hereinafter in effect (the “Bankruptcy Code”), or fails to controvert in a timely manner, or acquiesces to, any petition filed against it in an involuntary case under
the Bankruptcy Code; or 

  
 20 

 (b) a proceeding or case is commenced against Oncogenerix in relation to an Insolvency Event
or similar relief under the Bankruptcy Code in the Territory. For avoidance of doubt, all rights and licenses granted under or pursuant to any section of this Agreement are, and shall otherwise be deemed to be, for purposes of Section 365(n) of
the U.S. Bankruptcy Code, licenses of “intellectual property” as defined thereunder. The parties shall retain and may fully exercise all of their respective rights and elections under the Bankruptcy Code. 

12.5 Termination for Withdrawal of Licensed Product from the Market. Either party may terminate this Agreement in its entirety
upon thirty (30) days’ prior written notice if the Licensed Product is withdrawn from the market or recalled in any country or countries in the Territory for safety reasons, and has been off the market for at least six (6) months;

 12.6 Termination by Rosemont. Rosemont may terminate this Agreement in its entirety upon thirty (30) days’ prior
written notice if Oncogenerix fails to generate Net Revenues of a least US$3,000,000 (three million US dollars) within the first twenty four (24) months commencing on the date of first Commercial Sale of the Licensed Product in the Territory
(“initial sales period”) or thereafter if Oncogenerix fails to generate Net Revenues of at least US$3,000,000 (three million US dollars) within each subsequent twelve (12) month period after the initial sales period; provided,
however, that Rosemont shall not be entitled to terminate this Agreement pursuant to this Section 12.7 if Oncogenerix’s failure to generate such Net Revenues has been caused by Rosemont’s failure to supply Product (as defined in the
Supply Agreement) to Oncogenerix in accordance with the terms of the Supply Agreement. 
 12.7 Mutual Termination. This
Agreement may be terminated at any time by a written agreement signed by both Parties. 
 12.8 Termination for Force Majeure
Event. Notwithstanding anything to the contrary contained in this Agreement, in the event that a Force Majeure Event shall have occurred and be continuing for one hundred and eighty (180) consecutive days, either party shall be entitled to
terminate this Agreement upon thirty (30) days written notice to the other party. 
 12.9 Consequences of
Termination. 
 (a) Upon termination of this Agreement, any and all affected rights and licenses granted by Rosemont to
Oncogenerix shall terminate on the effective date of termination, except as otherwise set forth herein. For avoidance of doubt, any licenses granted by Oncogenerix to Rosemont shall continue and shall survive termination of this Agreement.

 (b) Upon expiration or termination of this Agreement due to reasons other than by Rosemont’s termination pursuant to
Sections 12.4 to 12.7, Oncogenerix may continue using the licenses granted hereunder to undertake the Activities in respect of all Licensed Product which are fully manufactured and in Oncogenerix’s (including its Affiliates’) inventory and
for which there is a binding order on Oncogenerix (or its Affiliates) at the date of such expiry or termination for a period of time not to exceed six (6) months from such expiry or termination date (the “Tail

  
 21 

 
Period”) (provided that such sales shall be subject to the Royalties and milestone payment obligations under Article VI of this Agreement, as well as all payment obligations under the
Supply Agreement). Oncogenerix (and its Affiliates) shall destroy any inventory of Licensed Product which has not been sold during the Tail Period and provide to Rosemont a sworn declaration evidencing such destruction. 

(c) Upon termination of this Agreement, each party shall return or destroy all copies of the other party’s Confidential Information
(together with any and all summaries and extracts thereof), and certify to the other party that all copies of the other party’s Confidential Information have been returned or destroyed. 

(d) During the Tail Period the grants under Section 2.1 and Section 3.1(e) and under this Agreement shall become non-exclusive.

 (e) Upon expiry or termination of this Agreement for any reason, Oncogenerix shall assign to Rosemont, at no cost to
Rosemont, all rights and title to all know-how, Oncogenerix Data and information related to the Activities relating to the Licensed Product. 
 12.10 Non-Exclusive Remedy for Breach. In the event of breach, the Non-Breaching Party may terminate this Agreement, as specified in Section 12.4, but may also seek damages or other remedies
to which the Non-Breaching Party may be entitled. The provisions of Section 12.4 are not intended to be exclusive and are without prejudice to the rights of the parties to enforce any other rights, and seek any other remedies, which they may
have under this Agreement or otherwise.. 
 12.11 Survival. Unless expressly provided to the contrary, the provisions of
Sections 3.1(e) (Ownership of Data and Regulatory Approvals), 7.2 (Accounting), 7.3 (Audit), 7.4 (Methods of Payment), 7.5 (Taxes), 10.1 (Improvements), 11.1 (Enforcement of Patent Rights/Trademarks), 12.10 (Consequences of Termination), 12.11
(Non-exclusive Remedy for Breach), 16.8 (Notices) and 16.9 (Choice of Law), and Articles VI (Payment), VIII (Ownership of Technology and Intellectual Property), XIII (Confidentiality, Disclosure and Publications), XIV (Dispute Resolution) and XV
(Indemnification) shall survive the termination of this Agreement and shall expire on their own terms, or if no expiration is expressly indicated therein, shall continue indefinitely. 

12.12 Except for the purpose of disposing of Licensed Products during the Tail Period provided by this Section 12, Oncogenerix shall
not during any notice period and after termination of this Agreement from whatever cause: 
 (a) promote, market or advertise
the Licensed Products; and/or 
 (b) enter into any further negotiation or commitment for the sale or other disposition of the
Licensed Products and shall cease to hold itself out as being an authorised distributor of Rosemont in respect of the Licensed Products, except for the purpose of fulfilling orders accepted by it prior to the date of termination. 

  
 22 

 12.13 During any notice period, Rosemont may, to the extent that Oncogenerix (and/or its
Affiliates) is unable or unwilling to supply the Licensed Products to customers in the Territory in accordance with Section 12.10(b) above, supply Licensed Products directly to customers in the Territory in order to fulfill any customer orders
existing prior to the termination date. 
 12.14 Oncogenerix (and its Affiliates) shall, at no additional cost to Rosemont,
promptly provide such assistance and comply with such timetable as Rosemont may reasonably require for the purpose of ensuring an orderly transfer of responsibility to Rosemont or a third party, as Rosemont may determine in its sole discretion, upon
the expiry or other termination of this Agreement for any reason whatsoever. Rosemont shall be entitled to require the provision of such assistance both prior to and, for a reasonable period of time after the expiry or other termination of this
Agreement. 
 12.15 Oncogenerix undertakes that it shall not knowingly do or omit to do anything which may adversely affect the
ability of Rosemont (and/or its Affiliates) to ensure an orderly transfer of responsibility. 
 12.16 Oncogenerix (and/or its
Affiliates) shall not be entitled to any claims, compensation or damages arising out of the valid termination of this Agreement in accordance with this Agreement nor to any payment for goodwill which may have been established or to any similar
payment notwithstanding any provision or rule of law to the contrary. 
 XIII. CONFIDENTIALITY, DISCLOSURE AND
PUBLICATIONS 
 13.1 Treatment of Confidential Information. Except as provided below, the parties agree that
during the Term, and for a period of three (3) years thereafter, each party (the “Receiving Party”) shall (i) maintain in confidence Confidential Information of the other party (the “Disclosing Party”) to
the same extent and with the same degree of care as the Receiving Party maintains its own proprietary information of similar kind and value (but at a minimum each party shall use Reasonable Diligence), (ii) not disclose such Confidential
Information to any Third Party without prior written consent of the Disclosing Party, except for disclosures made in confidence to any Third Party, and (iii) not use such Confidential Information for any purpose except those permitted by this
Agreement. Each party shall neither disclose to the other party nor induce the other party to use any secret or Confidential Information belonging to a Third Party. 
 13.2 Exceptions. Notwithstanding the foregoing, the Receiving Party shall have no such confidentiality obligations with respect to any portion of the Confidential Information of the Disclosing
Party that the Receiving Party can prove: 
 (a) at the time of disclosure by the Disclosing Party to the Receiving Party, was
generally available to the public, or after such disclosure, becomes generally available to the public through no fault attributable to the Receiving Party or its Affiliates; or 

(b) was known to the Receiving Party or its Affiliate, without obligation to keep it confidential, prior to when it was received from the
Disclosing Party; or 

  
 23 

 (c) is subsequently disclosed to the Receiving Party or its Affiliate, without obligation to
keep it confidential, by a Third Party lawfully in possession thereof and having the right to so disclose; or 
 (d) is
demonstrated by the Receiving Party by competent written proof, has been independently developed by the Receiving Party or its Affiliate who do not have access to or knowledge of such Confidential Information; or 

(e) is disclosed pursuant to a court order, law, or regulation, provided that the Receiving Party provides the other party prior written
notice of the required disclosure and takes reasonable steps to limit such disclosure to the minimum required by such court order, law, or regulation and to obtain, or cooperate with the other party in obtaining, a protective order or other similar
order requiring that such Confidential Information be used only for the purposes required by such court order, law, or regulation; 
 provided
always that the Receiving Party is seeking to rely upon any of the exceptions set out above then the Confidential Information shall not be deemed to be within one of the exceptions set out above merely because it is embraced by more general
information within such exceptions. In addition, any combinations of features disclosed by the Disclosing Party will be deemed to be within the public domain only if both the combination itself and its use fall within the exception set out above.

 13.3 Authorized Disclosures. Nothing in this Agreement shall prohibit the Receiving Party from disclosing Confidential
Information of the Disclosing Party, as well as the terms and conditions of this Agreement, to: 
 (a) the Receiving
Party’s Affiliates, officers, employees, agents, consultants, sublicensees, advisors (other than professional advisors), clinical institution and investigators, and contract manufacturers and suppliers, if any, but only on a need-to-know basis
for purposes provided for in this Agreement, provided such disclosure occurs pursuant to a confidentiality agreement containing provisions at least as protective as those of this Article XIII; 

(b) the Receiving Party’s board of directors and professional advisors (such as attorneys and accountants) bound by a duty of
confidentiality; or 
 (c) potential collaborators, acquirers or merger candidates, provided such disclosure occurs pursuant to
a confidentiality agreement containing provisions at least as protective as those of this Article XIII. 
 13.4
Publicity. All publicity, press releases, and other public announcements relating to this Agreement or the performance hereunder shall be reviewed in advance by, and subject to the approval of, both parties (which approval shall not be
unreasonably withheld, conditioned, or delayed); provided, however, that any disclosure which a party is required by law or any listing or securities trading agreement concerning its publicly traded securities (if applicable), based upon advice of
such party’s legal advisors, may be made without the prior consent of the other party, although the other party shall be given prompt notice (but in no event later than the time the actual disclosure is made) of any such legally required
disclosure and to the extent practicable, the disclosing party shall provide the other party an opportunity to comment on the proposed disclosure. 

  
 24 

 13.5 [not used] 
 XIV. DISPUTE RESOLUTION 
 14.1 Jurisdiction. Subject to
Section 14.2 below, any claim, dispute or controversy arising out of or in connection with or relating to this Agreement or the breach or alleged breach thereof shall be submitted by the parties to the exclusive jurisdiction of the courts of
England and Wales. 
 14.2 No Limitation on Injunctive Relief. Nothing in this Agreement shall be deemed as preventing
Rosemont from seeking injunctive relief (or any other provisional remedy) from any court having jurisdiction in the Territory and the subject matter of the dispute as necessary to protect its name, proprietary information, trade secrets, know-how or
any other proprietary right. 
 14.3 Any dispute between the parties in connection with this Agreement shall be referred in the
first instance to the dispute resolution procedure in this Section 14. 
 14.4 Initial meeting. In the first
instance the relevant contract manager for each of the parties shall arrange to meet solely in order to resolve the matter in dispute. Such meeting shall be minuted and shall be chaired by the party calling for the meeting (but the chairman shall
not have a casting vote). 
 14.5 Managerial escalation. (a) If the meeting referred to in Section 14.4 above
does not resolve the matter in question within ten (10) Business Days of the date of that meeting being called, then the parties will escalate the matter to the Managing Directors of each of the parties. 

(b) The Managing Directors referred to above shall arrange to meet solely in order to resolve the matter in dispute. Such meeting shall
be minuted and shall be chaired by the party calling for the meeting (but the chairman shall not have a casting vote). 
 (c)
The meetings referred to in this Section 14.5 shall be conducted in such manner and at such venue (including a meeting conducted by telephone or video conference) as to promote a consensual resolution of the dispute in question to the mutual
satisfaction of the parties. 
 (d) If the matter has not been resolved within thirty (30) days from the referral of the
dispute under Section 14.4, either party may initiate binding arbitration as set out in Section 14.6 below. 
 14.6
The dispute shall be referred to and finally resolved by binding arbitration under the Rules of Arbitration of the International Chamber of Commerce by one or more arbitrators appointed in accordance with such Rules. The seat, or legal place, of
arbitration shall be London and the language used to conduct the arbitral proceedings shall be English. 

  
 25 

 XV. INDEMNIFICATION 

15.1 Indemnification by Oncogenerix. 
 (a) Oncogenerix shall defend, indemnify, keep indemnified and hold harmless Rosemont (including its Affiliates), its trustees, directors, officers, agents and employees from and against any and all Third
Party suits, Claims, proceedings, acts, liabilities, demands, damages, costs, expenses (including legal expenses and disbursements) (“Losses”), including those resulting from death, personal injury, illness or property damage
arising (i) out of the distribution, use, testing/handling, Promotion, marketing, sale or storage, and/or Activities by Oncogenerix, an Affiliate of Oncogenerix, or any distributor, sublicensee or representative of Oncogenerix or anyone in
privity therewith (other than Rosemont), of any Licensed Product in the Territory, to the extent that such distribution, use, testing/handling, Promotion, marketing, sale or storage, and/or Activities is not in accordance with any written
instructions provided by Rosemont; (ii) out of any breach by Oncogenerix of any representation, warranty or covenant of this Agreement; (iii) out of any violation of applicable law by an action, policy or procedure of Oncogenerix or its
Affiliates or any distributor, sublicensees or representative of Oncogenerix or anyone in privity therewith (other than Rosemont); or (iv) out of any negligence or willful misconduct of Oncogenerix or its Affiliates; in each case except to the
extent that Rosemont is liable for such Losses pursuant to Section 15.2; provided that Oncogenerix’s liability under this Section 15.1 in any Year will, where permitted by law, be limited to US$5,000,000 in aggregate. Anything to the
contrary notwithstanding, Losses shall not include any indirect loss of profits or revenues, or any loss of good will. 
 (b)
Oncogenerix shall obtain and maintain in force for the Term and for a period of three (3) years thereafter adequate and suitable insurance with a reputable insurance company to cover its liability under this Agreement and shall supply to
Rosemont certificates to prove that Oncogenerix has appropriate and valid insurance. Oncogenerix shall obtain and maintain product liability insurance cover of a minimum of US$5,000,000 per claim or series of linked claims. 

(c) For the avoidance of doubt, Oncogenerix shall continue to be liable under all provisions of this Agreement whether or not they comply
with the provisions of Section 15.1(b). 
 15.2 Indemnification by Rosemont. Rosemont agrees to defend, indemnify
and hold harmless Oncogenerix, its directors, officers, and employees from and against any Third Party Claims related to or Losses resulting from death, personal injury, illness or property damage arising as a result of: (i) the manufacture or
the supply of the Licensed Products by Rosemont to Oncogenerix; (ii) any breach by Rosemont of its obligations under this Agreement; (iii) any violation of applicable law by Rosemont; (iv) any negligence or willful misconduct of
Rosemont; (v) any failure by Rosemont to implement a withdrawal or recall of the Licensed Product in the Territory; provided that Rosemont’s liability under this Agreement (including the Technical Agreement and the Supply Agreement) will
be limited to US$5,000,000 in aggregate. Rosemont shall not be liable for any indirect and/or consequential loss or for any loss of profit, loss of business, loss of opportunity, loss of anticipated contracts, loss of anticipated savings, loss of
goodwill whether such loss is direct or indirect. Each type of loss in this Section 15.2 shall be severable in accordance with Section 16.7. 

  
 26 

 15.3 Procedure. In the event of a claim by a Third Party against a party entitled to
indemnification under this Agreement (“Indemnifying Party”), the Indemnified Party shall promptly notify the other party (“Indemnified Party”) in writing of the claim and the Indemnifying Party shall undertake and
solely manage and control, at its sole expense, the defense of the claim and its settlement. The Indemnified Party shall cooperate with the Indemnifying Party, including, as requested by the Indemnifying Party and at the Indemnifying Party’s
cost, entering into a joint defense agreement. The Indemnified Party may, at its option and expense, be represented in such action or proceeding by counsel of its choice. The Indemnifying Party shall not be liable for any litigation costs or
expenses incurred by the Indemnified Party without the Indemnifying Party’s written consent. The Indemnifying Party shall not settle any such claim unless such settlement fully and unconditionally releases the Indemnified Party from all
liability relating thereto, unless the Indemnified Party otherwise agrees in writing. 
 15.4 Nothing in this Section 15 or
this Agreement is intended to and/or shall limit or exclude either party’s liability for death or personal injury resulting from its negligence, or any liability for fraud, fraudulent, misrepresentation or any other liability that could be
restricted by law. 
 XVI. MISCELLANEOUS 
 16.1 Mutual Representations and Warranties. Each party represents and warrants to the other party hereto that, except as may otherwise be disclosed in writing to such party: 

(a) it has the full right and authority to enter into this Agreement and to perform its obligations hereunder; 

(b) it is duly organized, validly existing, and in good standing under the laws of its jurisdiction of incorporation; 

(c) this Agreement is a legal and valid obligation binding upon it and is enforceable in accordance with its terms; 

(d) its execution, delivery and performance of this Agreement will not conflict with the terms of any other agreement or instrument to
which it is or becomes a party or by which it is or becomes bound, nor violate any law or regulation of any court, governmental body or administrative or other agency having authority over it; 

(e) neither it, nor any of its employees or agents performing hereunder, are listed on the debarment list maintained by the FDA pursuant
to 21 U.S.C. § 335(a) and § 335(b). 
 (f) such party has obtained all consents, approvals and authorizations of all
relevant government authorities and other persons required to be obtained by it as of the Effective Date in connection with the execution, delivery and performance of this Agreement; and 

  
 27 

 (g) no agent, broker, investment banker, financial advisor or other person, is or will be
entitled to any brokers’ or finder’s fee or any other commission or similar fee in connection with any of the transactions contemplated by this Agreement from such party. 

16.2 Oncogenerix Covenants, Representations and Warranties. 

Compliance with Law. Oncogenerix covenants that it (and its Affiliates) shall comply, and cause its employees, sublicensees and
agents to comply, with all federal, state, provincial, territorial, governmental, and local laws, rules, and regulations applicable to the Activities, Promotion and commercialization of the Licensed Product, including without limitation, with
respect to the Territory, the Prescription Drug Marketing Act, the Federal Food, Drug and Cosmetics Act of 1938, as amended (the “Act”), the Health Insurance Portability and Accountability Act (“HIPAA”), the Federal
Anti-Kickback Statute, and any applicable FDA regulations in connection therewith. 
 16.3 Rosemont Covenants,
Representations and Warranties 
 (a) Exclusivity, NDA and Intellectual Property. Rosemont hereby warrants to
Oncogenerix that, with respect to the Licensed Product, as of the Effective Date: (i) it has not previously granted, and is not currently obligated to grant, to any Third Party the rights granted to Oncogenerix hereunder in the Field in the
Territory with respect to the Licensed Product, and (ii) to the best of Rosemont’s knowledge, as of the Effective Date no person other than Rosemont or its Affiliates has any right, title or interest in any of the Licensed Know-How
Controlled by Rosemont or its Affiliates within the Field in the Territory. 
 (b) Compliance with Law. Rosemont
covenants that it shall use its best efforts to comply, and cause its employees and agents to use their respective best efforts to comply, with all relevant and applicable federal, state, provincial, territorial, governmental, local laws, rules, and
regulations, permits, governmental licenses, registrations, approvals, concessions, franchises, authorizations, orders, injunctions and decrees applicable to the development, manufacture, Promotion, use and sale of the Licensed Product, including
without limitation, with respect to the Territory, the Prescription Drug Marketing Act, the Act, HIPAA, the Federal Anti-Kickback Statute, and any applicable FDA regulations in connection therewith (“Laws”) to the extent that such
Laws (and any amendments made thereto) are notified to Rosemont by Oncogenerix. 
 16.4 Assignment. 

(a) By Oncogenerix. Oncogenerix may assign this Agreement and the licenses herein granted to: (i) any Affiliate;
(ii) any Third Party purchaser of all or substantially all of Oncogenerix’s business to which this Agreement relates; or (iii) any Third Party other than a Third Party purchaser of Oncogenerix’s business, only with the prior
written consent of Rosemont and subject to the provisions of Section 2.1(c). 

  
 28 

 (b) By Rosemont. Rosemont may assign, novate, dispose of, sub-licence, sub-contract
or otherwise transfer this Agreement and its rights and obligations hereunder to: (i) any Affiliate without Oncogenerix’s consent, provided that Rosemont remains fully liable for the performance of its obligations hereunder by such
Affiliate, (ii) any Third Party purchaser of all or substantially all of Rosemont’s business to which this Agreement relates, without Oncogenerix’s consent; or (iii) any Third Party other than a Third Party purchaser of
Rosemont’s business, with the prior written notice to Oncogenerix. 
 (c) If a party assigns this Agreement to a Third
Party purchaser of it or its business, then such party shall use its reasonable endeavours to ensure that such Third Party purchaser agrees to be responsible for the obligations set forth in this Agreement to the extent that such obligations are
incurred after the effective date of such assignment. 
 (d) This Agreement shall be binding on and shall inure to the benefit
of the permitted successors and assigns of the parties hereto. 
 16.5 Entire Agreement; Modification. This Agreement
(including its schedules, exhibits and appendices) together with the Supply Agreement, Rosemont’s then current standard Terms and Conditions of Sale from time to time, and the Technical Agreement constitutes the entire agreement between the
parties hereto with respect to the subject matter herein and supersedes all previous agreements, whether written or oral. Each party acknowledges and agrees that in entering into this Agreement it places no reliance on any representation or warranty
in relation to the subject matter of this Agreement other than as expressly set out in this Agreement, nor shall have any remedy in relation to the subject matter of the same save as expressly set out in this Agreement. Nothing in this
Section 16.5 or in this Agreement shall operate to exclude or restrict any remedy or liability for fraud or fraudulent misrepresentation. Each of the parties agree that its only remedy in respect of those representations, statements, assurances
and warranties that are set out in this Agreement will be for breach of contract, and that this remedy is subject to the terms of this Agreement. This Agreement shall not be changed or modified orally, but only by an instrument in writing signed by
both parties. 
 16.6 Force Majeure. Subject to the provisions of Section 12.9, if either party is delayed,
interrupted in or prevented from the performance of any obligation hereunder by reason of a force majeure event, including an act of God, fire, flood, earthquake, war (declared or undeclared), public disaster, act of terrorism, governmental
enactment, rule or regulation, or any other cause beyond such party’s control (“Force Majeure Event”), such party shall not be liable to the other therefor; and the time for performance of such obligation shall be extended for
a period equal to the duration of the Force Majeure Event which occasioned the delay, interruption or prevention. The party invoking such Force Majeure Event rights of this Section 16.6 must (a) notify the other party by courier or
overnight dispatch (e.g., Federal Express) within a period of ten (10) business days of both the first and last day of the Force Majeure Event unless the Force Majeure Event renders such notification impossible in which case notification will
be made as soon as possible and (b) uses commercially reasonable efforts to cause the event of the Force Majeure Event to terminate, be cured or otherwise ended, to the extent possible. 

16.7 Severability. If any provision of this Agreement is declared invalid by a court or other competent body, or by any court or
other governmental body from the decision of which an 

  
 29 

 
appeal is not taken within the time provided by law, then this Agreement will be deemed to have been terminated only as to the portion thereof that relates to the provision invalidated by that
decision and only in the relevant jurisdiction, but this Agreement, in all other respects and all other jurisdictions, will remain in force; provided, however, that if the provision so invalidated is essential to the Agreement as a whole, then the
parties shall negotiate in good faith to amend the terms hereof as nearly as practical to carry out the original intent of the parties. 
 16.8 Notices. Any notice or report required or permitted to be given under this Agreement shall be made in writing in the English language and shall be mailed by certified or registered mail, or
facsimile and confirmed by mailing, as follows and shall be effective five (5) days after such mailing: 
  

					
		 	If to Oncogenerix:	  	Oncogenerix, Inc.
		 		  	3069 Pignatelli Crescent
		 		  	Mt. Pleasant, SC 29466
		 		  	Attention: President
		 		  	Fax: +001 (843) 388-0282
			
		 	If to Rosemont:	  	Rosemont Pharmaceuticals Ltd.
		 		  	Rosemont House, Yorkdale Industrial Park
		 		  	Braithwaite Street
		 		  	Leeds LS11 9XE
		 		  	England
		 		  	Attention: Managing Director
		 		  	Fax: +44 (0)113 245 3567

 16.9 Choice of Law. The validity, performance, construction, and effect of this Agreement shall be
governed by the laws of England and Wales without regard to any conflicts of law principles. 
 16.10 Publicity. No party
to this Agreement shall use the name of the other parties in any publicity release without the prior written permission of such other party, which shall not be unreasonably withheld. The other party shall have a reasonable opportunity to review and
comment on any such proposed publicity release. Except as required by law, no party hereto shall publicly disclose the terms of this Agreement or its terms and conditions unless expressly authorized to do so by the other party, which authorization
shall not be unreasonably withheld. In the event that disclosure is authorized, the parties will work together to develop a mutually acceptable disclosure. 
 16.11 Further Assurances. The parties agree to reasonably cooperate with each other in connection with any actions required to be taken as part of their respective obligations under this Agreement,
and shall (a) furnish to each other such further information; (b) execute and deliver to each other such other documents; and (c) do such other acts and things (including working collaboratively to correct any clerical, typographical,
or other similar errors in this Agreement), all as the other party may reasonably request for the purpose of carrying out the intent of this Agreement. 

  
 30 

 16.12 Expenses. Except as otherwise expressly provided in this Agreement, each party
shall pay its own expenses and costs incidental to the preparation of this Agreement and to the consummation of the transactions contemplated hereby. 
 16.13 Independent Contractor. Neither party is, nor will be deemed to be an employee, agent or representative of the other party for any purpose. Each party is an independent contractor, not an
employee or partner of the other party. Nothing in this Agreement is intended nor shall be construed as creating or establishing any agency, partnership or corporate relationship between the parties. Neither party shall have the authority to speak
for, represent or obligate the other party in any way without prior written authority from the other party. 
 16.14 No
Waiver. Any omission or delay by either party at any time to enforce any right or remedy reserved to it, or to require performance of any of the terms, covenants or provisions hereof, by the other party, shall not constitute a waiver of such
party’s rights to the future enforcement of its rights under this Agreement. Any waiver by a party of a particular breach or default by the other party shall not operate or be construed as a waiver of any subsequent breach or default by the
other party. 
 16.15 No Implied Licenses. Except as expressly provided herein, no right or license under any patent
application, issued patent, trademark, know-how or other proprietary information is granted, or shall be granted, by implication. 
 16.16 No Strict Construction. This Agreement has been prepared jointly by the parties and shall not be strictly construed against either party. 

16.17 Headings and Interpretation. The captions used herein are inserted for convenience of reference only and shall not be
construed to create obligations, benefits, or limitations. Any lists or examples following the word ‘including’ shall be interpreted without limitation to the generality of the preceding words. Words denoting
‘persons’ shall include individuals, bodies, corporate, unincorporated associations and partnerships. 
 16.18
Counterparts. This Agreement may be executed in counterparts, all of which taken together shall be regarded as one and the same instrument. Signatures provided by facsimile transmission shall be deemed to be original signatures. 

16.19 Third Party Rights. An entity which is not expressly a party to this Agreement shall have no right under the Contract
(Rights of Third Parties) Act 1999 to enforce any term of this Agreement and the provisions of that Act shall be expressly excluded from this Agreement. For the avoidance of doubt, any of Rosemont’s Affiliates may enforce its rights under this
Agreement. 
 (Remainder of Page Intentionally Left Blank; Signature Page Follows.) 

  
 31 

 IN WITNESS WHEREOF, the parties have executed this Exclusive Distribution Agreement through
their duly authorized representatives to be effective as of the Effective Date. 
  

									
	ONCOGENERIX, INC.	 		 	ROSEMONT PHARMACEUTICALS LTD.
					
	By:	  	 /s/ Christopher Clement
	 		 	By:	 	 /s/ John Blythe

					
	Name:	  	 Christopher Clement
	 		 	Name:	 	 John Blythe

					
	Title:	  	 President
	 		 	Title:	 	 Director

					
	Date:	  	 29th June, 2011
	 		 	Date:	 	 29th June 2011

  
 32 

 Exhibit A 
 Technical Agreement 

 Technical agreement on tasks and the division of responsibilities in the supply of materials from
Rosemont Pharmaceuticals to Oncogenerix. 
  

			
	 Version Number
	 	 Page Number

	1.0	 	Page 1 of 7

  

 Technical agreement on tasks and the division of responsibilities in 

the supply of materials from Rosemont Pharmaceuticals to 
 Oncogenerix 
 June 28th, 2011 

 Technical agreement on tasks and the division of responsibilities in the supply of materials from
Rosemont Pharmaceuticals to Oncogenerix. 
  

			
	 Version Number
	 	 Page Number

	1.0	 	Page 2 of 7

  

 Table of Contents 

 

					
			
	1	 	INTRODUCTION	  	3
			
	2	 	OBJECT OF THE AGREEMENT	  	3
			
	3	 	FACILITIES, EQUIPMENT, AND PERSONNEL	  	4
			
	4	 	STARTING AND PACKAGING MATERIALS	  	4
			
	5	 	MANUFACTURE, METHODS AND RECORDS	  	4
			
	6	 	QUALITY CONTROL AND TEST RECORDS	  	4
			
	7	 	COMPLAINTS AND RECALL	  	5
			
	8	 	CONTRACTING OF THIRD PARTIES	  	5
			
	9	 	CONCLUDING PROVISIONS	  	5

 Technical agreement on tasks and the division of responsibilities in the supply of materials from
Rosemont Pharmaceuticals to Oncogenerix. 
  

			
	 Version Number
	 	 Page Number

	1.0	 	Page 3 of 7

  

 Technical agreement on tasks and the division of responsibilities in the supply

 of materials from Rosemont Pharmaceuticals to Oncogenerix 
 The following Agreement has been concluded between: 
 Oncogenerix, Inc. –
(CG – Contract Giver) 
 and 
 Rosemont Pharmaceuticals Ltd – (CA – Contract Acceptor) 

For the supply of: 
 Soltamox®
(tamoxifen liquid, 10 mg / 5 mL, 150 mL) 
 And other finished products as specified in commercial agreements 

 

	1	Introduction 

  

	 	a)	In the pharmaceutical sector, material supply means the supply of material or drug product with responsibility divided; the CA, on its own responsibility,
produces, packs and inspects the material in accordance with agreed procedures, and any deviation from the written arrangements must be notified to the CG. 

 

	 	b)	This Agreement is primarily a technical agreement and does not purport to be exhaustive in relation to legal issues. Therefore, arrangements on prices and other
commercial terms (in particular; presentation, delivery times, liability, guarantees and confidentiality) should be described in a separate agreement. 

  

	 	c)	In the manufacture, packaging and / or testing of the material, the CA must follow, where appropriate, the European GMP (2003/94/EC), US GMP, (21 CFR Part
211), and/or all other applicable (inter)national rules and guidelines. 

  

	 	d)	If the CA and the CG are to designate contact names and details for all technical pharmaceutical matters, the appropriate contact persons
are named in Appendix 1. 

  

	2	Object of the Agreement 

  

	 	a)	The provisions of this Agreement apply to all orders for material that are issued after this Agreement is signed and before its termination is effected. They also apply
to existing orders issued by the CG to the CA that have not been substantially completed at the date of this Agreement. 

  

	 	b)	Appendix 2 contains: 

  

	 	i)	A list specifying how the responsibilities are defined between the CG and the CA, for each material. 

 

	 	ii)	A sample of certificates of compliance and certificate of analysis to be provided with each delivery of material. 

 Technical agreement on tasks and the division of responsibilities in the supply of materials from
Rosemont Pharmaceuticals to Oncogenerix. 
  

			
	 Version Number
	 	 Page Number

	1.0	 	Page 4 of 7

  

	3	Facilities, Equipment, and Personnel 

  

	 	a)	The facilities and equipment used by the CA to manufacture, test and perform the release activity will be maintained in accordance with current Good
Manufacturing Practice (cGMP). They should be located, designed and constructed to facilitate cleaning, maintenance and operations, as appropriate for the type of manufacture involved. 

 

	 	b)	Equipment used by the CA in the manufacture of the material should be of appropriate design, materials, construction, size and suitability to allow for
its intended use, cleaning and maintenance. 

  

	 	c)	All CA personnel responsible for the manufacturing, packaging, testing, or approval of drug products shall be appropriately trained and educated and
conform to applicable GMP regulations. 

  

	4	Starting and Packaging Materials 

  

	 	a)	The CA is responsible for the proper quality of the starting materials that it purchases. They will be inspected by the CA for quality and
identity, and released for use, in accordance with written procedures. 

  

	5	Manufacture, Methods and Records 

  

	 	a)	The CA is to manufacture in accordance with Good Manufacturing Practice according to current guidance. 

 

	 	b)	Appropriate systems must be in place for the documentation and management of process deviations or planned changes. 

 

	 	c)	For every material manufactured and / or analysed, the CA is to retain the documentation of starting materials and manufactured material.

  

	6	Quality Control and Test Records 

  

	 	a)	Quality assurance and control on the part of the CA will be the responsibility of the CA’s Quality Department.

  

	 	b)	The CA will provide tot eh CG; a Certificate of Compliance and a Certificate of Analysis for each batch of material produced or packed, each
will signed approval by the Person Responsible for Quality. 

  

	 	c)	The CG will receive the agreed documentation for each batch of material, as laid down in Appendix 2, at the same time as the relevant material’s
delivery. 

  

	 	d)	The CA will provide to the CG quality control samples and QC data/documents as requested. 

 Technical agreement on tasks and the division of responsibilities in the supply of materials from
Rosemont Pharmaceuticals to Oncogenerix. 
  

			
	 Version Number
	 	 Page Number

	1.0	 	Page 5 of 7

  

	7	Complaints and Recall 

  

	 	a)	The CG will notify the CA in writing of any complaints received concerning the material supplied, within seven calendar days of the receipt
of the complaint, and will require a written response from the CA to the complaint within 30 calendar days of the receipt of the complaint. 

  

	8	Contracting of Third Parties 

  

	 	a)	If the CA does not do the work covered by this Agreement itself, but agrees to sub-contract it to third parties, any such agreement made between the
CA and a third party must contain, as minimum, the same contractual obligations as those defined in this Agreement. All such agreements must receive prior approval from the CG. 

 

	9	Concluding Provisions 

  

	 	a)	This Agreement comes into force when signed by both contracting parties. It is valid for a three year period, after which the CG has the responsibility to
initiate a review. 

  

	 	b)	This agreement can be terminated by either party, in accordance with the commercial terms. 

 

	 	c)	Amendments and addenda to this Agreement and its appendices may be made only by mutual agreement, and must be defined in writing. Mutually agreed procedures come into
force automatically without signing a new agreement. 

 Signed on behalf of: 

Contract Giver 
  

			
		  	/s/ M. L. Radomsky
		
		  	Name Michael L. Radomsky
		
		  	Title VP, Development and Manufacturing
		
		  	Date 29 July 2011
		
	Contract Acceptor	  	
		
		  	/s/ John Robertson
		
		  	Name John K. Robertson
		
		  	Title QA Manager
		
		  	Date 22nd July 2011

 Technical agreement on tasks and the division of responsibilities in the supply of materials from
Rosemont Pharmaceuticals to Oncogenerix. 
  

			
	 Version Number
	 	 Page Number

	1.0	 	Page 6 of 7

  

 Appendix 1: 
  

							
		 	Responsible People
		
		 	Person responsible for Quality:
		
		 	Contract Giver:
				
		 		 	Name:	  	Michael Radomsky
				
		 		 	Title:	  	VP, Development and Manufacturing
		
		 	Contact Acceptor:
				
		 		 	Name:	  	John Robertson
				
		 		 	Title:	  	Quality Assurance Manager

 Technical agreement on tasks and the division of responsibilities in the supply of materials from
Rosemont Pharmaceuticals to Oncogenerix. 
  

			
	 Version Number
	 	 Page Number

	1.0	 	Page 7 of 7

  

 Appendix 2 
 Division of Pharmaceutical Responsibilities 
 Drug Product 

CG: Oncogenerix, Inc. 
 CA: Rosemont Pharmaceuticals Ltd 
  

							
	 	  	Contract Giver	  	Contract Acceptor	  	 
			
	Active Ingredient	  		  	
	Specification	  	 ̈	  	x	  	
	Purchase	  	 ̈	  	x	  	
	Testing	  	 ̈	  	x	  	
	Storage	  	 ̈	  	x	  	
	Other Starting Materials	  		  	
	Specification	  	 ̈	  	x	  	
	Purchase	  	 ̈	  	x	  	
	Testing	  	 ̈	  	x	  	
	Storage	  	 ̈	  	x	  	
	Primary Packing Materials	  		  	
	Specification	  	 ̈	  	x	  	
	Purchase	  	 ̈	  	x	  	
	Testing	  	 ̈	  	x	  	
	Storage	  	 ̈	  	x	  	
	
	 Documentation Required

 

	 	  	Every Consignment	  	On Request	  	 
			
	Primary Packaging Materials	  		  	
	 Certificate of testing
	  	  ̈
	  	 x
	  	
	API	  		  		  	
	 Certificate of Analysis
	  	  ̈
	  	 x
	  	
	Finished Product	  		  	
	 Certificate of Analysis
	  	 x
	  	  ̈
	  	
	 QP Certificate of Compliance
	  	 x
	  	  ̈
	  	

 Exhibit B 

Supply Agreement 

The terms and conditions of this Exhibit B and Rosemont’s standard Terms and Conditions of Sale (from time to time) shall apply to the supply and
purchase of the Licensed Products. 
 Supply of the Products: 

 

	1.	Rosemont shall sell and Oncogenerix shall purchase the Licensed Products and such quantities of the Licensed Products as are ordered by Oncogenerix, subject to
Rosemont’s standard Terms and Conditions of Sale from time to time, a current copy as at the Effective Date is attached to this Exhibit B; anything to the contrary notwithstanding, any Terms and Conditions of Sale shall not be contrary to, or
in contravention of, the terms set forth in the Agreement. 

  

	2.	Unless otherwise agreed in writing, orders for the Licensed Products shall be given by Oncogenerix submitting a purchase order to Rosemont. No order placed by
Oncogenerix shall be deemed to have been accepted by Rosemont, and orders for the Licensed Products shall become binding upon Rosemont issuing an order acknowledgement to Oncogenerix; to the extent that Rosemont fails to submit an order
acknowledgement to Oncogenerix within ten (10) Business Days of receipt of a purchase order then the order shall be considered accepted and binding upon Rosemont. 

 

	3.	For the avoidance of doubt, this Agreement shall expressly exclude any standard terms and conditions of purchase or other terms and conditions that Oncogenerix may
purport to apply under this Agreement or under any purchase order. 

  

	4.	The following terms of Rosemont’s standard Terms and Conditions of Sale shall not apply under this Agreement; clause 1.2 (the Price), clause 12 (United Kingdom
Regulations) and clause 13 (Patents and Trade Marks). The United Nations Convention on Contracts for the International Sale of Goods is expressly excluded under this Supply Agreement. 

Forecasting and Ordering: 
  

	5.	Oncogenerix shall supply a rolling twelve (12) month forecast of its estimated requirements for the Licensed Products to be updated on a quarterly basis
detailing final confirmation of Oncogenerix’s requirements for the Licensed Products for the following three (3) months. 

 Delivery: 
  

	6.	Delivery of the Licensed Products shall be CIF (cost insurance freight) to a mutually agreed upon port within the USA, in accordance with the International
Chamber of Commerce INCOTERMS 2010 at Rosemont’s site at the address first written in this Agreement. Time for delivery shall not be of the essence for the purposes of this Agreement. 

	7.	Rosemont will endeavour to comply with the reasonable requests of Oncogenerix for postponement of delivery of the Licensed Products but shall be under no
obligation to do so. Where delivery is postponed at the request of Oncogenerix, and which is otherwise than due to default by Rosemont, Oncogenerix, shall without prejudice to all other rights and remedies available to Rosemont, pay all costs and
expenses, including a reasonable charge for storage and transportation incurred by Rosemont as a result of such postponement. 

  

	8.	Rosemont may deliver the Licensed Products in separate instalments. Each separate instalment shall be invoiced and paid for in accordance with the provisions of this
Agreement. Any failure by Rosemont to delivery or claim by Oncogenerix in respect of any one or more of the instalments in accordance with this Agreement shall not entitled Oncogenerix to treat this Supply Agreement and/or this Agreement as a whole
as repudiated. 

 Price and Payment: 
  

	1.	The Price for the Licensed Products shall be US$10.25 per bottle of the Licensed Products. The Price shall be exclusive of VAT (or such other applicable sales taxes).
Time for payment shall be of the essence for the purposes of this Agreement. 

  

	2.	The Price for the Licensed Products may be increased each Year in line with RPI upon discussion and mutual agreement between both parties. 

 

	3.	If Oncogenerix fails to make a payment to Rosemont of any sums owed in the timescale specified in this Agreement, Rosemont shall be entitled, without prejudice to any
other right or remedy, to do all or any of the following: 

  

	 	a.	suspend without notice any or all further deliveries of the Licensed Product under this Agreement and any other contract(s) between Rosemont and Oncogenerix; and/or

  

	 	b.	serve notice on Oncogenerix requiring immediate payment of all Licensed Products supplied by Rosemont by Rosemont under this and all other contracts with Oncogenerix
whether or not payment is otherwise due. 

  

	4.	Except as expressly permitted under the terms of this Agreement, Oncogenerix shall not have the right to withhold or deduct any amounts payable under this Agreement
(whether by way of set-off or otherwise) owing to Rosemont from sums due to Rosemont under this Agreement. 

  
 36 

 Exhibit C 
 Commercialisation of Licensed Products 

	1.	Literature 

 1.1
Oncogenerix shall prepare and make in appropriate languages at its own expenses all necessary sales, technical, advertising and Promotional Material relating to the Licensed Product for use in the Territory. 

1.2 Oncogenerix shall be solely responsible for the translation and the accuracy or otherwise such Promotional Material created by
it whether or not the same is based on literature supplied by Rosemont or has been approved by Rosemont. 
 1.3 To the
extent practicable, all Promotional Materials shall state that the Licensed Products were developed or manufactured (as appropriate) by Rosemont and are Rosemont’s Licensed Products. 

 

	2.	Stock of Licensed Products 

Oncogenerix shall comply with all laws from time to time in force in the Territory relating to the Activities regarding the Licensed
Products. 
  

	3.	Reporting 

  

	 	3.1	Oncogenerix shall: 

  

	 	3.1.1	prepare and submit all reports to Rosemont as required by this Agreement in the form reasonably stipulated by Rosemont; 

 

	 	3.1.2	notify Rosemont without delay of all prosecutions, indictments and other like proceedings threatened or commenced against Oncogenerix, its Affiliates or sublicensees by
reason of any failure of the Licensed Products to meet the conditions and standard required by the laws relating to the Licensed Products in the Territory; 

 

	 	3.1.4	promptly submit to Rosemont particulars of all customer complaints received by it directly pertaining to the Licensed Products and use Reseasonable Diligence to
ascertain the nature and justification of such complaints and, where possible and practicable, assist customers to overcome all problems encountered by them in relation to the Licensed Products; and 

 

	 	3.1.5	keep detailed records of all technical faults and problems encountered by it in relation to the Licensed Products and its use and operation and provide Rosemont as
events occur with a report of such record and a comprehensive fault analysis extracted by such records. 

	4.	General Obligations 

  

	 	4.1	Oncogenerix shall: 

  

	 	4.1.1	be responsible for procuring such import licences, certificates of origin or other requisite documents in relation to the Licensed Products as shall from time to time
be required and bear the cost of obtaining the same and, if required by Rosemont, make available such import licences to Rosemont prior to the relevant shipment; and 

 

	 	4.1.2	not represent itself impliedly or expressly to be the agent of, or to have any authority to bind, Rosemont nor pledge its credit. 

  
 38 

 Exhibit D 
 Additional Products 
 The Additional Products set out in this Exhibit D
shall not be binding on Rosemont and serve as an illustration of the potential Additional Products under Section 3.1(d). 
 Allopurinol

 Metoclopramide 
 Procyclidine

 Simvastatin 

  
 39EX-10.38

 Exhibit 10.38 
 SECURITIES PURCHASE AGREEMENT 
 This Securities Purchase Agreement (this
“Agreement”) is dated as of             , 2012, between DARA BioSciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on
the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). 
 WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Securities
Act”), the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. 

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the
receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows: 
 ARTICLE I.

 DEFINITIONS 
 1.1 Definitions. In addition to the terms defined elsewhere in this Agreement: (a) capitalized terms that are not otherwise defined herein have the meanings given to such terms in the
Certificate of Designation (as defined herein), and (b) the following terms have the meanings set forth in this Section 1.1: 
 “Acquiring Person” shall have the meaning ascribed to such term in Section 4.5. 
 “Action” shall have the meaning ascribed to such term in Section 3.1(j). 
 “Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person as such terms are used
in and construed under Rule 405 under the Securities Act. 
 “Board of Directors” means the
board of directors of the Company. 
 “Business Day” means any day except any Saturday, any
Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close. 

“Certificate of Designation” means the Certificate of Designation to be filed prior to the Closing by the
Company with the Secretary of State of Delaware, in the form of Exhibit A attached hereto 

“Closing” means the closing of the purchase and sale of the Securities pursuant to Section 2.1.

  
 1 

 “Closing Date” means the Trading Day on which all of the
Transaction Documents have been executed and delivered by the applicable parties thereto, and all conditions precedent to (i) the Purchasers’ obligations to pay the Subscription Amount and (ii) the Company’s obligations to
deliver the Securities, in each case, have been satisfied or waived. The Closing Date is expected to be on or about             , 2012. 

“Commission” means the United States Securities and Exchange Commission. 

“Common Stock” means the common stock of the Company, par value $0.01 per share, and any other class of
securities into which such securities may hereafter be reclassified or changed. 
 “Common Stock
Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other
instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock. 
 “Company Counsel” means K&L Gates LLP, with offices located at 4350 Lassiter at North Hills Avenue, Suite 300, Raleigh, North Carolina 27609. 

“Conversion Price” shall have the meaning ascribed to such term in the Certificate of Designation.

 “Conversion Shares” shall have the meaning ascribed to such term in the Certificate of
Designation. 
 “Disclosure Schedules” means the Disclosure Schedules of the Company delivered
concurrently herewith. 
 “EGS” means Ellenoff Grossman & Schole LLP, with offices
located at 150 East 42nd Street, New York, New York 10017. 
 “Escrow Agent” means Signature
Bank, a New York State chartered bank and having an office at 261 Madison Avenue, New York, New York 10016. 

“Escrow Agreement” means the escrow agreement entered into prior to the date hereof, by and among the
Company, Ladenburg Thalmann & Co., Inc., and the Escrow Agent pursuant to which the Purchasers shall deposit Subscription Amounts with the Escrow Agent to be applied to the transactions contemplated hereunder. 

“Evaluation Date” shall have the meaning ascribed to such term in Section 3.1(r). 

“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations
promulgated thereunder. 

  
 2 

 “Exempt Issuance” means the issuance of (a) shares of
Common Stock or options to employees, officers, directors, or consultants of or to the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of
the members of a committee of non-employee directors established for such purpose, (b) securities upon the exercise or exchange of or conversion of any Securities issued hereunder and/or other securities exercisable or exchangeable for or
convertible into shares of Common Stock issued and outstanding on the date of this Agreement, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise
price, exchange price or conversion price of such securities, and (c) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that any such issuance
shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company
additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in
securities. 
 “FDA” shall have the meaning ascribed to such term in Section 3.1(gg).

 “FDCA” shall have the meaning ascribed to such term in Section 3.1(gg). 

“GAAP” shall have the meaning ascribed to such term in Section 3.1(h). 

“Indebtedness” shall have the meaning ascribed to such term in Section 3.1(z). 

“Intellectual Property Rights” shall have the meaning ascribed to such term in Section 3.1(o).

 “Liens” means a lien, charge, pledge, security interest, encumbrance, right of first refusal,
preemptive right or other restriction. 
 “Material Adverse Effect” shall have the meaning
assigned to such term in Section 3.1(b). 
 “Material Permits” shall have the meaning
ascribed to such term in Section 3.1(m). 
 “Person” means an individual or corporation,
partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. 

“Pharmaceutical Product” shall have the meaning ascribed to such term in Section 3.1(gg).

  
 3 

 “Preferred Stock” means the up to
             shares of the Company’s Series B-2 Convertible Preferred Stock issued hereunder having the rights, preferences and privileges set forth in the Certificate of Designation,
in the form of Exhibit A hereto. 
 “Proceeding” means an action, claim, suit,
investigation or proceeding (including, without limitation, an informal investigation or partial proceeding, such as a deposition), whether commenced or threatened. 

“Prospectus” means the final prospectus filed for the Registration Statement. 

“Prospectus Supplement” means the supplement to the Prospectus complying with Rule 424(b) of the
Securities Act that is filed with the Commission and delivered by the Company to each Purchaser at the Closing. 

“Purchaser Party” shall have the meaning ascribed to such term in Section 4.8. 

“Registration Statement” means the effective registration statement with Commission file
No. 333-179637 which registers the sale of the Preferred Stock, the Warrants and the Underlying Shares to the Purchasers. 
 “Required Approvals” shall have the meaning ascribed to such term in Section 3.1(e). 
 “Rule 144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation
hereafter adopted by the Commission having substantially the same effect as such Rule. 
 “Rule
424” means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the
same purpose and effect as such Rule. 
 “SEC Reports” shall have the meaning ascribed to such
term in Section 3.1(h). 
 “Securities” means the Preferred Stock, the Warrants, the
Warrant Shares and the Underlying Shares. 
 “Securities Act” means the Securities Act of 1933,
as amended, and the rules and regulations promulgated thereunder. 
 “Short Sales” means all
“short sales” as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed to include the location and/or reservation of borrowable shares of Common Stock).

“Stated Value” means $1,000 per share of Preferred Stock. 

  
 4 

 “Subscription Amount” means, as to each Purchaser, the
aggregate amount to be paid for the Preferred Stock and Warrants purchased hereunder as specified below such Purchaser’s name on the signature page of this Agreement and next to the heading “Subscription Amount,” in United States
dollars and in immediately available funds. 
 “Subsidiary” means any subsidiary of the Company
as set forth on Schedule 3.1(a), and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof. 

“Trading Day” means a day on which the principal Trading Market is open for trading. 

“Trading Market” means any of the following markets or exchanges on which the Common Stock is listed or
quoted for trading on the date in question: the NYSE AMEX, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York Stock Exchange (or any successors to any of the foregoing). 

“Transaction Documents” means this Agreement, the Certificate of Designation, the Warrants, the Escrow
Agreement and any other documents or agreements executed in connection with the transactions contemplated hereunder. 
 “Transfer Agent” means American Stock Transfer & Trust Company LLC, the current transfer agent of the Company, with a mailing address of 6201 15th Avenue, 2nd Floor, Brooklyn,
New York 11219 and a facsimile number of (718) 921-8323, and any successor transfer agent of the Company. 

“Underlying Shares” means the shares of Common Stock issued and issuable upon conversion or redemption of
the Preferred Stock and upon exercise of the Warrants. 
 “Warrants” means, collectively, the
Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a) hereof, which Warrants shall be exercisable immediately and have a term of exercise equal to five years, in the form of Exhibit C
attached hereto. 
 “Warrant Shares” means the shares of Common Stock issuable upon exercise of
the Warrants. 
 ARTICLE II. 
 PURCHASE AND SALE 
 2.1 Closing. On the Closing Date, upon the terms and
subject to the conditions set forth herein, substantially concurrent with the execution and delivery of this Agreement by the parties hereto, the Company agrees to sell, and the Purchasers, severally and not jointly, agree to purchase, up to an
aggregate of $         of shares of Preferred Stock with an aggregate Stated Value for each Purchaser equal to such Purchaser’s Subscription Amount as set forth on the signature page hereto executed by
such Purchaser, and Warrants as determined by pursuant to Section 2.2(a). The aggregate number of shares of Preferred Stock sold hereunder shall be up to             . Each Purchaser
shall deliver to the Escrow Agent, via wire 

  
 5 

 
transfer or a certified check of immediately available funds equal to such Purchaser’s Subscription Amount as set forth on the signature page hereto executed by such Purchaser and the
Company shall deliver to each Purchaser its respective shares of Preferred Stock and a Warrant as determined pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver the other items set forth in Section 2.2 deliverable
at the Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall occur at the offices of EGS or such other location as the parties shall mutually agree. 

2.2 Deliveries. 
 (a) On or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following: 

(i) this Agreement duly executed by the Company; 

(ii) a legal opinion of Company Counsel, substantially in the form of Exhibit B attached hereto; 

(iii) a certificate evidencing a number of shares of Preferred Stock equal to such Purchaser’s Subscription Amount
divided by the Stated Value, registered in the name of such Purchaser and evidence of the filing and acceptance of the Certificate of Designation from the Secretary of State of Delaware; 

(iv) a Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to
    % of such Purchaser’s Subscription Amount divided by the initial Conversion Price, with an exercise price equal to $        , subject to adjustment therein (such Warrant
certificate may be delivered within three Trading Days of the Closing Date); 
 (v) a Warrant registered in the
name of such Purchaser to purchase up to a number of shares of Common Stock equal to     % of such Purchaser’s Subscription Amount divided by the initial Conversion Price, with an exercise price equal to
$        , subject to adjustment therein (such Warrant certificate may be delivered within three Trading Days of the Closing Date); and 

(vi) the Prospectus and Prospectus Supplement (which may be delivered in accordance with Rule 172 under the Securities
Act). 
 (b) On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the
Company or the Escrow Agent, as applicable, the following: 
 (i) this Agreement duly executed by such Purchaser;
and 
 (ii) to the Escrow Agent, such Purchaser’s Subscription Amount by wire transfer to the account as
specified in the Escrow Agreement. 
 2.3 Closing Conditions. 

  
 6 

 (a) The obligations of the Company hereunder in connection with the Closing
are subject to the following conditions being met: 
 (i) the accuracy in all material respects on the Closing
Date of the representations and warranties of the Purchasers contained herein (unless as of a specific date therein); 
 (ii) all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been performed; and 

(iii) the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement. 

(b) The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following
conditions being met: 
 (i) the accuracy in all material respects when made and on the Closing Date of the
representations and warranties of the Company contained herein (unless as of a specific date therein); 
 (ii)
all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed; 
 (iii) the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement; 
 (iv) there shall have been no Material Adverse Effect with respect to the Company since the date hereof; and 
 (v) from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission (except for any suspension of trading of limited duration agreed to by the
Company, which suspension shall be terminated prior to the Closing), and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall not have been suspended or limited, or minimum prices shall not have
been established on securities whose trades are reported by such service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities nor shall there have occurred any
material outbreak or escalation of hostilities or other national or international calamity of such magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of each Purchaser,
makes it impracticable or inadvisable to purchase the Securities at the Closing. 

  
 7 

 ARTICLE III. 
 REPRESENTATIONS AND WARRANTIES 
 3.1 Representations and Warranties of the
Company. Except as otherwise disclosed in the Registration Statement, or the Company’s Annual Report on Form 10-K for the year ended December 31, 2011, any Company Quarterly Report on Form 10-Q filed since the filing date of such
Annual Report, or any of the Company’s Current Reports on Form 8-K filed since the filing date of such Annual Report (including any exhibit thereto and document incorporated by reference therein), and except as set forth in the Disclosure
Schedules (it being agreed that disclosure of any item in any section or subsection of the Disclosure Schedules shall be deemed to be disclosed with respect to any other section or subsection thereof or hereof to which the relevance of such
disclosure is readily apparent), which Disclosure Schedules shall be deemed a part hereof, the Company hereby makes the following representations and warranties to each Purchaser: 

(a) Subsidiaries. All of the direct and indirect subsidiaries of the Company are set forth on Schedule
3.1(a). Except as set forth on Schedule 3.1(a), the Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding shares of
capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights to subscribe for or purchase securities. If the Company has no subsidiaries, all other references to the Subsidiaries or
any of them in the Transaction Documents shall be disregarded. 
 (b) Organization and Qualification. The
Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to own
and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or
other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business
conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in: (i) a material adverse effect on
the legality, validity or enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a
whole, or (iii) a material adverse effect on the Company’s ability to perform in any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a “Material Adverse
Effect”) and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification. 

(c) Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into and to
consummate the transactions contemplated by each of the Transaction Documents and otherwise to carry out its 

  
 8 

 
obligations hereunder and thereunder. The execution and delivery of each of the Transaction Documents by the Company and the consummation by it of the transactions contemplated hereby and thereby
have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, the Board of Directors or the Company’s stockholders in connection therewith other than in connection with the
Required Approvals. Each Transaction Document to which it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and binding
obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general
application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and
contribution provisions may be limited by applicable law. 
 (d) No Conflicts. The execution, delivery and
performance by the Company of the Transaction Documents, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby to which it is a party do not and will not (i) conflict with or
violate any provision of the Company’s or any Subsidiary’s certificate or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or
lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, acceleration or cancellation (with
or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any
property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction
of any court or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected; except in
the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect. 
 (e) Filings, Consents and Approvals. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or
other federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings required pursuant to
Section 4.4 of this Agreement, (ii) the filing with the Commission of the Prospectus Supplement, (iii) application(s) to each applicable Trading Market for the listing of the Underlying Shares and Warrant Shares for trading thereon,
and (iv) such filings as are required to be made under applicable state securities laws (collectively, the “Required Approvals”). 
 (f) Issuance of the Securities; Registration. The Securities are duly authorized and, when issued and paid for in accordance with the applicable Transaction

  
 9 

 
Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company other than restrictions on transfer provided for in the Transaction
Documents. The Underlying Shares, when issued in accordance with the terms of the Transaction Documents, will be validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company other than restrictions on transfer
provided for in the Transaction Documents. The Company has reserved from its duly authorized capital stock a number of shares of Common Stock for issuance of all of the Underlying Shares on the date hereof. The Company has prepared and filed the
Registration Statement in conformity with the requirements of the Securities Act, which became effective on                     , 2012 (the
“Effective Date”), including the Prospectus, and such amendments and supplements thereto as may have been required to the date of this Agreement. The Registration Statement is effective under the Securities Act and no stop order
preventing or suspending the effectiveness of the Registration Statement or suspending or preventing the use of the Prospectus has been issued by the Commission and no proceedings for that purpose have been instituted or, to the knowledge of the
Company, are threatened by the Commission. The Company, if required by the rules and regulations of the Commission, proposes to file the Prospectus with the Commission pursuant to Rule 424(b). At the time the Registration Statement and any
amendments thereto became effective, at the date of this Agreement and at the Closing Date, the Registration Statement and any amendments thereto conformed and will conform in all material respects to the requirements of the Securities Act and did
not and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading; and the Prospectus and any amendments or supplements
thereto, at time the Prospectus or any amendment or supplement thereto was issued and at the Closing Date, conformed and will conform in all material respects to the requirements of the Securities Act and did not and will not contain an untrue
statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. 

(g) Capitalization. The capitalization of the Company is as set forth on Schedule 3.1(g). Except as set
forth on Schedule 3.1(g), the Company has not issued any capital stock since its most recently filed periodic report under the Exchange Act, other than pursuant to the exercise of employee stock options under the Company’s stock plans,
the issuance of shares of Common Stock to employees pursuant to the Company’s employee stock plans and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the most recently filed periodic report
under the Exchange Act. No Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents. Except as a result of the purchase and
sale of the Securities, there are no outstanding options (other than employee, director and consultant stock options), warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or
obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary
is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents. The issuance and sale of the Securities will not obligate the Company to issue shares of Common Stock or other securities to any Person (other than the
Purchasers) and 

  
 10 

 
will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset price under any of such securities. All of the outstanding shares of capital
stock of the Company are validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights
to subscribe for or purchase securities. No further approval or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale of the Securities. There are no stockholders agreements, voting agreements or
other similar agreements with respect to the Company’s capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company’s stockholders. 

(h) SEC Reports; Financial Statements. The Company has filed all reports, schedules, forms, statements and other
documents required to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof since February 12, 2008 (the foregoing materials, including the exhibits thereto and
documents incorporated by reference therein, together with the Prospectus and the Prospectus Supplement, being collectively referred to herein as the “SEC Reports”) on a timely basis or has received a valid extension of such time of
filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable,
and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading. The Company has never been an issuer subject to Rule 144(i) under the Securities Act. The financial statements of the Company included in the SEC Reports comply in all material respects with applicable
accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been prepared in accordance with United States generally accepted accounting principles
applied on a consistent basis during the periods involved (“GAAP”), except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes
required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject,
in the case of unaudited statements, to normal, immaterial, year-end audit adjustments. 
 (i) Material
Changes; Undisclosed Events, Liabilities or Developments. Since the date of the latest audited financial statements included within the SEC Reports, except as specifically disclosed in a subsequent SEC Report filed prior to the date hereof,
(i) there has been no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than
(A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the Company’s financial statements pursuant to GAAP or disclosed in
filings made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any 

  
 11 

 
dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v) the Company
has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock plans. The Company does not have pending before the Commission any request for confidential treatment of information. Except for
the issuance of the Securities contemplated by this Agreement or as set forth on Schedule 3.1(i), no event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with
respect to the Company or its Subsidiaries or their respective business, properties, operations, assets or financial condition that would be required to be disclosed by the Company under applicable securities laws at the time this representation is
made or deemed made that has not been publicly disclosed at least 1 Trading Day prior to the date that this representation is made. 
 (j) Litigation. There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any
Subsidiary or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an “Action”) which
(i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material
Adverse Effect. Neither the Company nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of
fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission involving the Company or any current or former director or officer of the Company. The Commission has
not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act. 

(k) Labor Relations. No material labor dispute exists or, to the knowledge of the Company, is imminent with respect
to any of the employees of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company’s or its Subsidiaries’ employees is a member of a union that relates to such employee’s
relationship with the Company or such Subsidiary, and neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their relationships with their employees are
good. No executive officer, to the knowledge of the Company, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement,
or any other contract or agreement or any restrictive covenant in favor of any third party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability with respect to any of
the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours,
except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. 

  
 12 

 (l) Compliance. Except as set forth on Schedule 3.1(l),
neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary
under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or
any of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator or governmental body or (iii) is or has been in violation of any
statute, rule, ordinance or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws applicable to its business and all such laws that affect the environment, except in each case as could not
have or reasonably be expected to result in a Material Adverse Effect. 
 (m) Regulatory Permits. The
Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports,
except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (“Material Permits”), and neither the Company nor any Subsidiary has received any notice of proceedings
relating to the revocation or modification of any Material Permit. 
 (n) Title to Assets. The Company and
the Subsidiaries have good and marketable title in fee simple to all real property owned by them and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries, in each case
free and clear of all Liens, except for Liens as do not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and Liens for the
payment of federal, state or other taxes, the payment of which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries are held by them under valid, subsisting and
enforceable leases with which the Company and the Subsidiaries are in compliance. 
 (o) Patents and
Trademarks. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual
property rights and similar rights necessary or material for use in connection with their respective businesses as described in the SEC Reports and which the failure to so have could have a Material Adverse Effect (collectively, the
“Intellectual Property Rights”). Neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of the Intellectual Property Rights used by the Company or any Subsidiary violates or infringes upon the
rights of any Person. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have
taken reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual properties, except where failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect. 

  
 13 

 (p) Insurance. The Company and the Subsidiaries are insured by
insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including, but not limited to, directors and
officers insurance coverage at least equal to the aggregate Subscription Amount. Neither the Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or
to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost. 
 (q) Transactions With Affiliates and Employees. Except as set forth in the SEC Reports, none of the officers or directors of the Company and, to the knowledge of the Company, none of the employees
of the Company is presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services
to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such
employee has a substantial interest or is an officer, director, trustee or partner, in each case in excess of $120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred
on behalf of the Company and (iii) other employee benefits, including stock option or equity purchase agreements under any stock plan of the Company. 
 (r) Sarbanes-Oxley; Internal Accounting Controls. The Company is in material compliance with all provisions of the Sarbanes-Oxley Act of 2002 which are applicable to it as of the Closing Date. The
Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management’s general or specific authorizations,
(ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management’s general
or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company has established disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and designed such disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it files or
submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms. The Company’s certifying officers have evaluated the effectiveness of the Company’s
disclosure controls and procedures as of the end of the period covered by the Company’s most recently filed periodic report under the Exchange Act (such date, the “Evaluation Date”). The Company presented in its most recently
filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have
been no changes in the Company’s internal control over financial reporting (as such term is defined in the Exchange Act) that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over
financial reporting. 

  
 14 

 (s) Certain Fees. Except as set forth in the Prospectus Supplement,
no brokerage or finder’s fees or commissions are or will be payable by the Company to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by
the Transaction Documents. The Purchasers shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may be due in connection with the
transactions contemplated by the Transaction Documents. 
 (t) Investment Company. The Company is not, and
is not an Affiliate of, and immediately after receipt of payment for the Securities, will not be or be an Affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940, as amended. The Company shall conduct
its business in a manner so that it will not become an “investment company” subject to registration under the Investment Company Act of 1940, as amended. 

(u) Registration Rights. No Person has any right to cause the Company to effect the registration under the
Securities Act of any securities of the Company. 
 (v) Listing and Maintenance Requirements. The Common
Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock under the
Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such registration. Schedule 3.1(v) describes the most recent notification received by the Company from Nasdaq. 

(w) Application of Takeover Protections. The Company and the Board of Directors have taken all necessary action, if
any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti-takeover provision under the Company’s certificate of
incorporation (or similar charter documents) or the laws of its state of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company fulfilling their obligations or exercising their rights under
the Transaction Documents, including without limitation as a result of the Company’s issuance of the Securities and the Purchasers’ ownership of the Securities. 

(x) Disclosure. Except with respect to the material terms and conditions of the transactions contemplated by the
Transaction Documents, the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel with any information that it believes constitutes or might constitute material,
non-public information which is not otherwise disclosed in the Prospectus Supplement. The Company understands and confirms that the Purchasers will rely on the foregoing representation in effecting transactions in securities of the Company. All of
the disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company, its business and the transactions contemplated hereby, including the Disclosure Schedules to this Agreement, is true and correct and does not contain
any untrue statement 

  
 15 

 
of a material fact or omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. The Company
acknowledges and agrees that no Purchaser makes or has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof. Each press release issued by the
Company or any of its Subsidiaries during the twelve (12) months preceding the date of this Agreement did not at the time of release contain any untrue statement of a material fact or omit to state a material fact required to be stated therein
or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. 
 (y) No Aggregated Offering. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section 3.2, neither the Company, nor any of its Affiliates, nor any
Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities to be aggregated with prior
offerings by the Company for purposes of any applicable shareholder approval provisions of any Trading Market on which any of the securities of the Company are listed or designated. 

(z) Solvency. Based on the consolidated financial condition of the Company as of the Closing Date, after giving
effect to the receipt by the Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company’s assets exceeds the amount that will be required to be paid on or in respect of the Company’s
existing debts and other liabilities (including known contingent liabilities) as they mature, (ii) the Company’s assets do not constitute unreasonably small capital to carry on its business as now conducted and as proposed to be conducted
including its capital needs taking into account the particular capital requirements of the business conducted by the Company, and projected capital requirements and capital availability thereof, and (iii) the current cash flow of the Company,
together with the proceeds the Company would receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when such amounts
are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge of
any facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date. The periodic SEC Reports set forth as of
the date thereof all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes of this Agreement, “Indebtedness” means (x) any
liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of
others, whether or not the same are or should be reflected in the Company’s balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary
course of business; and (z) the present value of any lease payments in excess of $50,000 due under leases required to be capitalized 

  
 16 

 
in accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness. 

(aa) Tax Status. Except for matters that would not, individually or in the aggregate, have or reasonably be
expected to result in a Material Adverse Effect, the Company and each Subsidiary has filed all necessary federal, state and foreign income and franchise tax returns and has paid or accrued all taxes shown as due thereon, and the Company has no
knowledge of a tax deficiency which has been asserted or threatened against the Company or any Subsidiary. 

(bb) Foreign Corrupt Practices. Neither the Company, nor to the knowledge of the Company, any agent or other person
acting on behalf of the Company, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment
to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company (or made by any person acting on its
behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of the Foreign Corrupt Practices Act of 1977, as amended. 

(cc) Accountants. The Company’s accounting firm is set forth on Schedule 3.1(cc) of the Disclosure
Schedules. To the knowledge and belief of the Company, such accounting firm (i) is a registered public accounting firm as required by the Exchange Act and (ii) shall express its opinion with respect to the financial statements to be
included in the Company’s Annual Report for the year ending December 31, 2012. 
 (dd)
Acknowledgment Regarding Purchasers’ Purchase of Securities. The Company acknowledges and agrees that each of the Purchasers is acting solely in the capacity of an arm’s length purchaser with respect to the Transaction Documents and
the transactions contemplated thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions
contemplated thereby and any advice given by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely incidental to the Purchasers’
purchase of the Securities. The Company further represents to each Purchaser that the Company’s decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the transactions
contemplated hereby by the Company and its representatives. 
 (ee) Acknowledgement Regarding Purchaser’s
Trading Activity. Anything in this Agreement or elsewhere herein to the contrary notwithstanding (except for Sections 3.2(e) and 4.12 hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers have been asked
by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the Company, or “derivative” securities based on securities issued by the Company or to hold the Securities for
any specified term; (ii) past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short Sales or “derivative” 

  
 17 

 
transactions, before or after the closing of this or future private placement transactions, may negatively impact the market price of the Company’s publicly-traded securities; (iii) any
Purchaser, and counter-parties in “derivative” transactions to which any such Purchaser is a party, directly or indirectly, presently may have a “short” position in the Common Stock, and (iv) each Purchaser shall not be
deemed to have any affiliation with or control over any arm’s length counter-party in any “derivative” transaction. The Company further understands and acknowledges that (y) one or more Purchasers may engage in hedging activities
at various times during the period that the Securities are outstanding, including, without limitation, during the periods that the value of the Warrant Shares deliverable with respect to Securities are being determined, and (z) such hedging
activities (if any) could reduce the value of the existing stockholders’ equity interests in the Company at and after the time that the hedging activities are being conducted. The Company acknowledges that such aforementioned hedging
activities do not constitute a breach of any of the Transaction Documents. 
 (ff) Regulation M
Compliance. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of
the Company to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the Securities, or (iii) paid or agreed to pay to any Person any
compensation for soliciting another to purchase any other securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Company’s placement agent in connection with the placement of the Securities.

 (gg) FDA. As to each product subject to the jurisdiction of the U.S. Food and Drug Administration
(“FDA”) under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (“FDCA”) that is manufactured, packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of
its Subsidiaries (each such product, a “Pharmaceutical Product”), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance with all applicable
requirements under FDCA and similar laws, rules and regulations relating to registration, investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices,
product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company’s knowledge,
threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has
received any notice, warning letter or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing
or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or
sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company or any of
its Subsidiaries, (v) enters or proposes 

  
 18 

 
to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company
or any of its Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of the Company have been and are being conducted in all material respects in accordance
with all applicable laws, rules and regulations of the FDA, except where the failure to be in compliance would not have a Material Adverse Effect. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale,
license or use in the United States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern to the Company as to approving or clearing for marketing any product being developed or proposed
to be developed by the Company. 
 3.2 Representations and Warranties of the Purchasers. Each Purchaser, for itself and
for no other Purchaser, hereby represents and warrants as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein): 

(a) Organization; Authority. Such Purchaser is either an individual or an entity duly organized, validly existing
and in good standing under the laws of the jurisdiction of its organization with full right, corporate or partnership power and authority to enter into and to consummate the transactions contemplated by this Agreement and otherwise to carry out its
obligations hereunder and thereunder. The execution and delivery of this Agreement and performance by such Purchaser of the transactions contemplated by this Agreement have been duly authorized by all necessary corporate, partnership, limited
liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof,
will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization,
moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and
(iii) insofar as indemnification and contribution provisions may be limited by applicable law. 
 (b)
Understandings or Arrangements. Such Purchaser is acquiring the Securities as principal for its own account and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such
Securities (this representation and warranty not limiting such Purchaser’s right to sell the Securities pursuant to the Registration Statement or otherwise in compliance with applicable federal and state securities laws). Such Purchaser is
acquiring the Securities hereunder in the ordinary course of its business. 
 (c) Purchaser Status. At the
time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on which it exercises any Warrants or converts any shares of Preferred Stock, it will be either: (i) an “accredited investor” as
defined in Rule 501 under the Securities Act or (ii) a “qualified institutional buyer” as defined in Rule 144A(a) under the Securities Act. Such Purchaser is not required to be registered as a broker-dealer under Section 15 of
the Exchange Act. 

  
 19 

 (d) Experience of Such Purchaser. Such Purchaser, either alone or
together with its representatives, has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities, and has so evaluated the
merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment. 

(e) Certain Transactions and Confidentiality. Other than consummating the transactions contemplated hereunder, such
Purchaser has not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any purchases or sales, including Short Sales, of the securities of the Company during the period
commencing as of the time that such Purchaser first received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material pricing terms of the transactions contemplated hereunder and ending
immediately prior to the execution hereof. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser’s assets and the
portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser’s assets, the representation set forth above shall only apply with respect to the portion of assets
managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other than to other Persons party to this Agreement, such Purchaser has maintained the confidentiality of all disclosures made
to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any
actions, with respect to the identification of the availability of, or securing of, available shares to borrow in order to effect Short Sales or similar transactions in the future. 
 The Company acknowledges and agrees that the representations contained in Section 3.2 shall not modify, amend or affect such Purchaser’s right to rely on the Company’s representations and
warranties contained in this Agreement or any representations and warranties contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement or the consummation of the
transaction contemplated hereby. 
 ARTICLE IV. 
 OTHER AGREEMENTS OF THE PARTIES 
 4.1 Underlying Shares. The shares of
Common Stock underlying the shares of Preferred Stock shall be issued free of legends. If all or any portion of a Warrant is exercised at a time when there is an effective registration statement to cover the issuance or resale of the Warrant Shares
or if the Warrant is exercised via cashless exercise, the Warrant Shares issued pursuant to any such exercise shall be issued free of all legends. If at any time following the date hereof the Registration Statement (or any subsequent registration
statement registering the sale or resale of the Warrant Shares) is not effective or is not otherwise available for the sale or resale of the Warrant Shares, the Company shall immediately notify the holders of the Warrants in writing that such
registration statement is not then effective and thereafter shall immediately notify such holders when the registration statement is effective again and available for the sale or resale of 

  
 20 

 
the Warrant Shares (it being understood and agreed that the foregoing shall not limit the ability of the Company to issue, or any Purchaser to sell, any of the Warrant Shares in compliance with
applicable federal and state securities laws). The Company shall use best efforts to keep a registration statement (including the Registration Statement) registering the issuance or resale of the Warrant Shares effective during the term of the
Warrants. Upon a cashless exercise of a Warrant, the holding period for purposes of Rule 144 shall tack back to the original date of issuance of such Warrant. 
 4.2 Furnishing of Information. Until the earliest of the time that (i) no Purchaser owns Securities or (ii) the Warrants have expired, the Company covenants to timely file (or obtain
extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act even if the Company is not then subject to the reporting requirements of
the Exchange Act. As long as any Purchaser owns Securities, if the Company is not required to file reports pursuant to the Exchange Act, it will prepare and furnish to the Purchasers and make publicly available in accordance with Rule 144(c) such
information as is required for the Purchasers to sell the Securities, including without limitation, under Rule 144. The Company further covenants that it will take such further action as any holder of Securities may reasonably request, to the extent
required from time to time to enable such Person to sell such Securities without registration under the Securities Act, including without limitation, within the requirements of the exemption provided by Rule 144. 

4.3 Aggregation. The Company shall not sell any security (as defined in Section 2 of the Securities Act) that would be
aggregated with the sale of the Securities for purposes of any then-applicable rules and regulations of any Trading Market to the extent that such subsequent sale would require shareholder approval pursuant to such rules and regulations prior to the
closing thereof unless such shareholder approval is obtained prior to such closing. 
 4.4 Securities Laws Disclosure;
Publicity. The Company shall, by 8:30 a.m. (New York City time) on the Trading Day immediately following the date hereof, issue a press release disclosing the material terms of the transactions contemplated hereby, and, within the time period
required by the Securities Act, file a Form 8-K describing the transaction, and including the Transaction Documents as exhibits thereto. From and after the issuance of such press release, the Company represents to the Purchasers that it shall have
publicly disclosed all material, non-public information delivered to any of the Purchasers by the Company or any of its subsidiaries, or any of their respective officers, directors, employees or agents in connection with the transactions
contemplated by the Transaction Documents. The Company and each Purchaser shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby, and neither the Company nor any Purchaser shall issue
any such press release nor otherwise make any such public statement without the prior consent of the Company, with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with respect to any press release of
the Company (other than the press release described in the first sentence of this Section 4.4), which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in which case the disclosing party shall
promptly provide the other party with prior notice of such public statement or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser in any filing with
the Commission 

  
 21 

 
or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except (a) as required by federal securities law in connection with the filing of final
Transaction Documents with the Commission and (b) to the extent such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchasers with prior notice of such disclosure permitted under this
clause (b). 
 4.5 Shareholder Rights Plan. No claim will be made or enforced by the Company or, with the consent of the
Company, any other Person, that any Purchaser is an “Acquiring Person” under any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or similar anti-takeover plan or
arrangement in effect or hereafter adopted by the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents or under any other
agreement between the Company and the Purchasers. 
 4.6 Non-Public Information. Except with respect to the material
terms and conditions of the transactions contemplated by the Transaction Documents, the Company covenants and agrees that neither it, nor any other Person acting on its behalf will provide any Purchaser or its agents or counsel with any information
that the Company believes constitutes material non-public information, unless prior thereto such Purchaser shall have executed a written agreement with the Company regarding the confidentiality and use of such information. The Company understands
and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. 
 4.7 Use of Proceeds. Except as set forth on Schedule 4.7 attached hereto, the Company shall use the net proceeds from the sale of the Securities hereunder for working capital purposes.

 4.8 Indemnification of Purchasers. Subject to the provisions of this Section 4.8, the Company will indemnify and
hold each Purchaser and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other
title), each Person who controls such Purchaser (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners or employees (and any other
Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (each, a “Purchaser Party”) harmless from any and all losses, liabilities,
obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys’ fees and costs of investigation that any such Purchaser Party may suffer or incur as a
result of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents or (b) any action instituted against the Purchaser
Parties in any capacity, or any of them or their respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated by the Transaction Documents (unless such
action is based upon a breach of such Purchaser Party’s representations, warranties or covenants under the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such stockholder or any violations by
such Purchaser Party of state or federal securities laws or any conduct by such 

  
 22 

 
Purchaser Party which constitutes fraud, gross negligence, willful misconduct or malfeasance). If any action shall be brought against any Purchaser Party in respect of which indemnity may be
sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party.
Any Purchaser Party shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent that
(i) the employment thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (iii) in such action there is, in the
reasonable opinion of counsel, a material conflict on any material issue between the position of the Company and the position of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more
than one such separate counsel. The Company will not be liable to any Purchaser Party under this Agreement (y) for any settlement by a Purchaser Party effected without the Company’s prior written consent, which shall not be unreasonably
withheld or delayed; or (z) to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party’s breach of any of the representations, warranties, covenants or agreements made by such
Purchaser Party in this Agreement or in the other Transaction Documents. The indemnification required by this Section 4.8 shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when
bills are received or are incurred. The indemnity agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser Party against the Company or others and any liabilities the Company may be subject to
pursuant to law. 
 4.9 Reservation of Common Stock. As of the date hereof, the Company has reserved and the Company
shall continue to reserve and keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue the Underlying Shares pursuant to the Transaction Documents pursuant
to any conversion of the Preferred Stock or exercise of the Warrants. 
 4.10 Listing of Common Stock. The Company hereby
agrees to use reasonable efforts to maintain the listing or quotation of the Common Stock on the Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list or quote all of the Underlying Shares
and Warrant Shares on such Trading Market and promptly seek to secure the listing of all of the Underlying Shares and Warrant Shares on such Trading Market. The Company further agrees, if the Company applies to have the Common Stock traded on any
other Trading Market, it will then include in such application all of the Underlying Shares and Warrant Shares, and will take such other action as is necessary to cause all of the Underlying Shares and Warrant Shares to be listed or quoted on such
other Trading Market as promptly as possible. The Company will then take all action reasonably necessary to continue the listing and trading of its Common Stock on such other Trading Market and will comply in all respects with the Company’s
reporting, filing and other obligations under the bylaws or rules of the Trading Market. 
 4.11 Equal Treatment of
Purchasers. No consideration (including any modification of any Transaction Document) shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of any of this Agreement unless the same consideration

  
 23 

 
is also offered to all of the parties to this Agreement. For clarification purposes, this provision constitutes a separate right granted to each Purchaser by the Company and negotiated separately
by each Purchaser, and is intended for the Company to treat the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of Securities or
otherwise. 
 4.12 Certain Transactions and Confidentiality. Each Purchaser, severally and not jointly with the other
Purchasers, covenants that neither it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including Short Sales of any of the Company’s securities during the period commencing
with the execution of this Agreement and ending at such time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4. Each Purchaser, severally and
not jointly with the other Purchasers, covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described in Section 4.4, such Purchaser
will maintain the confidentiality of the existence and terms of this transaction and the information included in the Disclosure Schedules. Notwithstanding the foregoing and notwithstanding anything contained in this Agreement to the contrary,
the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation, warranty or covenant hereby that it will not engage in effecting transactions in any securities of the Company after the time that the transactions
contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4, (ii) no Purchaser shall be restricted or prohibited from effecting any transactions in any securities of the
Company in accordance with applicable securities laws from and after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4 and (iii) no
Purchaser shall have any duty of confidentiality to the Company or its Subsidiaries after the issuance of the initial press release as described in Section 4.4. Notwithstanding the foregoing, in the case of a Purchaser that is a
multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser’s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing
other portions of such Purchaser’s assets, the covenant set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this
Agreement. 
 4.13 Delivery of Warrants After Closing. The Company shall deliver, or cause to be delivered, the
respective Warrant certificates purchased by each Purchaser to such Purchaser within 3 Trading Days of the Closing Date. 
 4.14
[Reserved.] 

  
 24 

 ARTICLE V. 
 MISCELLANEOUS 
 5.1 Termination. This Agreement may be terminated by
any Purchaser, as to such Purchaser’s obligations hereunder only and without any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing has not been consummated
on or before                     , 2012; provided, however, that no such termination will affect the right of any party to sue for any
breach by the other party (or parties). 
 5.2 Fees and Expenses. Except as expressly set forth in the Transaction
Documents to the contrary, each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and
performance of this Agreement. The Company shall pay all Transfer Agent fees (including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any conversion or exercise notice delivered
by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers. 
 5.3 Entire Agreement. The Transaction Documents, together with the exhibits and schedules thereto, the Prospectus and the Prospectus Supplement contain the entire understanding of the parties with
respect to the subject matter hereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules. 

5.4 Notices. Any and all notices or other communications or deliveries required or permitted to be provided
hereunder shall be in writing and shall be deemed given and effective on the earliest of: (a) the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number set forth on the signature pages attached
hereto prior to 5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number set forth on the signature pages
attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2nd) Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service or
(d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto. 

  
 25 

 5.5 Amendments; Waivers. No provision of this Agreement may be waived, modified,
supplemented or amended except in a written instrument signed, in the case of an amendment, by the Company and the Purchasers holding at least 67% in interest of the Securities based on the initial Subscription Amounts hereunder or, in the case of a
waiver, by the party against whom enforcement of any such waived provision is sought. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a
waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right. 

5.6 Headings. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to
limit or affect any of the provisions hereof. 
 5.7 Successors and Assigns. This Agreement shall be binding upon and
inure to the benefit of the parties and their successors and permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser (other than by merger). Any
Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred Securities, by
the provisions of the Transaction Documents that apply to the “Purchasers.” 
 5.8 No Third-Party
Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as
otherwise set forth in Section 4.8 and except that Ladenburg Thalmann & Co., Inc. is an intended third-party beneficiary hereunder. 
 5.9 Governing Law. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed by and construed and enforced in accordance
with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by
this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, employees or agents) shall be commenced exclusively in the state and federal courts sitting
in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, borough of Manhattan for the adjudication of any dispute hereunder or in connection
herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any
claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and
consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this
Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other

  
 26 

 
manner permitted by law. If either party shall commence an action or proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company under
Section 4.8, the prevailing party in such action or proceeding shall be reimbursed by the other party for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such
action or proceeding. 
 5.10 Survival. The representations and warranties contained herein shall survive the Closing and
the delivery of the Securities for twenty-four (24) months. 
 5.11 Execution. This Agreement may be executed in two
or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties
need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party
executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature page were an original thereof. 
 5.12 Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the
terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ
an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed
the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable. 
 5.13 Rescission and Withdrawal Right. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any of the other Transaction Documents, whenever any
Purchaser exercises a right, election, demand or option under a Transaction Document and the Company does not timely perform its related obligations within the periods (including any cure periods) therein provided, then such Purchaser may rescind or
withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in whole or in part without prejudice to its future actions and rights; provided, however, that in the case of a
rescission of a conversion of the Preferred Stock or an exercise of a Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject to any such rescinded conversion or exercise notice concurrently with the return
to such Purchaser of the aggregate exercise price paid to the Company for such shares and the restoration of such Purchaser’s right to acquire such shares pursuant to such Purchaser’s Warrant (including, issuance of a replacement warrant
certificate evidencing such restored right). 
 5.14 Replacement of Securities. If any certificate or instrument
evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution therefor, a
new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction. The applicant for a 

  
 27 

 
new certificate or instrument under such circumstances shall also pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.

 5.15 Remedies. In addition to being entitled to exercise all rights provided herein or granted by law, including
recovery of damages, each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of any
breach of obligations contained in the Transaction Documents and hereby agree to waive and not to assert in any action for specific performance of any such obligation the defense that a remedy at law would be adequate. 

5.16 Payment Set Aside. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction
Document or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside,
recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other person under any law (including, without limitation, any bankruptcy law, state or federal law, common law or
equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such
enforcement or setoff had not occurred. 
 5.17 Independent Nature of Purchasers’ Obligations and Rights. The
obligations of each Purchaser under any Transaction Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance of the obligations of any
other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document, and no action taken by any Purchaser pursuant thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a
joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser
shall be entitled to independently protect and enforce its rights including, without limitation, the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined
as an additional party in any proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in their review and negotiation of the Transaction Documents. For reasons of administrative convenience only, each
Purchaser and its respective counsel have chosen to communicate with the Company through EGS. EGS does not represent any of the Purchasers and only represents Ladenburg Thalmann & Co., Inc. The Company has elected to provide all Purchasers
with the same terms and Transaction Documents for the convenience of the Company and not because it was required or requested to do so by any of the Purchasers. 
 5.18 Liquidated Damages. The Company’s obligations to pay any partial liquidated damages or other amounts owing under the Transaction Documents is a continuing obligation of the Company and
shall not terminate until all unpaid partial liquidated damages and other amounts have been paid notwithstanding the fact that the instrument or security pursuant to 

  
 28 

 
which such partial liquidated damages or other amounts are due and payable shall have been canceled. 
 5.19 Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such
action may be taken or such right may be exercised on the next succeeding Business Day. 
 5.20 Construction. The parties
agree that each of them and/or their respective counsel has reviewed and had an opportunity to revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the
drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments hereto. In addition, each and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to
adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement. 

5.21 WAIVER OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE
PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY. 

(Signature Pages Follow) 

  
 29 

 IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be
duly executed by their respective authorized signatories as of the date first indicated above. 
  

							
	DARA BIOSCIENCES, INC.	 		 	Address for Notice:
				
	By:	 	  
	 		 	Fax:
		 	Name:	 		 	
		 	Title:	 		 	
			
	With a copy to (which shall not constitute notice):	 		 	

 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK 

SIGNATURE PAGE FOR PURCHASER FOLLOWS] 

  
 30 

 [PURCHASER SIGNATURE PAGES TO DARA SECURITIES PURCHASE AGREEMENT] 

IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above. 
  

			
	Name of Purchaser:	 	  

			
		
	Signature of Authorized Signatory of Purchaser:	 	  

			
		
	Name of Authorized Signatory:	 	  

			
		
	Title of Authorized Signatory:	 	  

			
		
	Email Address of Authorized Signatory:	 	  

			
		
	Facsimile Number of Authorized Signatory:	 	  

			
		
	Address for Notice of Purchaser:	 	

 Address for Delivery of Securities for Purchaser (if not same as address for notice): 

Subscription Amount: $         
 Shares of Preferred Stock:              
 Warrant Shares:              
 EIN
Number:              
 [SIGNATURE PAGES CONTINUE] 

  
 31

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00202-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00202-of-00352.parquet"}]]